Comparative Outcomes of Split versus Whole Liver Transplantation in Adult ESLD Recipients: A Multicenter Propensity-Matched Analysis

Comparative Outcomes of Split versus Whole Liver Transplantation in Adult ESLD Recipients: A Multicenter Propensity-Matched Analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Comparative Outcomes of Split versus Whole Liver Transplantation in Adult ESLD Recipients: A Multicenter Propensity-Matched Analysis Yunguo Lei, Jun Pan, Zhe Yang, Jun Chen, Beng Yang, Zhisheng Zhou, and 7 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6432057/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract This multicenter study (2018–2022) compared split liver (SLT) vs. whole liver (WLT) transplantation in 5,978 adults (1,532 SLT; 4,446 WLT). Propensity-matched analysis showed HCC-SLT recipients had higher early allograft dysfunction (25.7% vs. 16.8%, P < 0.001) and pleural effusion (17.3% vs. 9.9%, P < 0.001) than HCC-WLT, while non-HCC ESLD-SLT recipients faced more intra-abdominal bleeding (13.5% vs. 8.5%, P = 0.02) and vascular complications (4.7% vs. 1.9%, P = 0.01). Despite these early risks, HCC cohorts achieved equivalent 5-year overall (OS) and disease-free survival (P > 0.05). Non-HCC ESLD recipients with right hemiliver/trisection grafts had superior 1-/3-year OS (82.2%/77.2% vs. 63.4%/57.8%, P 25, prolonged cold ischemia time (CIT), and exceeding Milan/Hangzhou criteria as HCC survival risks; age, CIT, and graft type predicted non-HCC mortality. SLT offers oncologically safe, long-term outcomes for HCC comparable to WLT with strict selection, while right-graft optimization and CIT reduction improve non-HCC ESLD survival. Health sciences/Gastroenterology/Hepatology/Liver Health sciences/Gastroenterology/Hepatology/Liver diseases Figures Figure 1 Figure 2 Figure 3 INTRODUCTION Liver transplantation (LT) is an effective treatment for end-stage liver disease, certain metabolic disorders, and liver tumors ( 1 ) ,with 2024 EASL guidelines reaffirming its therapeutic primacy in both curative and palliative contexts ( 2 )‌ ,yet donor liver shortages persist globally. China's organ supply-demand ratio reached 1:6 in 2021 ( 3 ) , necessitating innovative solutions like split liver transplantation (SLT) - a technique enabling dual/multiple recipients per donor liver through anatomical segmentation ( 4 ) . This technique theoretically doubles the donor pool, alleviating the shortage of donor livers and reducing the waiting time for recipients ( 5 ) . Currently, SLT is still evolving worldwide. According to the 2021 annual report of the United States Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR), 16.6% of pediatric liver transplants were SLT ( 6 ) , and the procedure is also widely practiced in Europe for pediatric cases ( 7 ) . Although SLT is well-established in pediatric transplantation, its use in adults remains limited ( 8 , 9 ) . SLT's technical complexity correlates with elevated risks of biliary/vascular complications ( 10 ) .In adults, split liver grafts are often considered riskier than whole liver grafts due to the potential for biliary and vascular complications resulting from the liver parenchyma transection, which can significantly impact graft and recipient survival ( 11 ) ( 12 ) . While some studies equate SLT and whole liver transplantation (WLT) safety ( 13 , 14 ) . Globally, the prognosis of SLT versus WLT in adults with hepatocellular carcinoma (HCC) and non-HCC end-stage liver disease (ESLD) is not well-documented,and evidence gaps persist regarding adult HCC vs. non-HCC ESLD outcomes (current literature) and donor-type impacts under China's unique C-I (DBD)/C-II (DCD)/C-III (DBCD) classification system ( 15 ) . Therefore, based on China Liver Transplant Registry(CLTR), we employed propensity score matching (PSM) - an advanced statistical approach that effectively balances confounding variables in observational research by creating comparable cohorts, thereby approximating randomized controlled trial conditions ( 16 ) .Through comprehensive univariate and multivariate Cox regression analyses, we identified and compared critical prognostic factors influencing overall survival (OS) in HCC versus non-HCC recipients. Furthermore, we conducted a novel lateralized analysis to investigate potential graft orientation-related outcomes by comparing postoperative prognoses between recipients of lefthemiliver versus right hemiliver and right trisegment grafts in SLT procedures.Finally, the study investigated the incidence of postoperative complications that occur following liver transplantation. Patients and Methods Study population The details liver transplants performed from January 2018 to December 2022 from 13 transplant centers in China, were collected by the CLTR. This was performed according to the Declaration of Helsinki (as revised in 2013) and approved by the CLTR (No. 20230030). Informed consent was obtained from all the patients for the use of their data for research purposes. Voluntarily donated organs from citizens have become the sole legitimate source of transplantable organs from deceased donors in China science January 2015 ( 15 – 16 ) . It is important to note that all deceased organ donations in China are nondirected donations. Additionally, to ensure fair, just, open, and traceable allocation, all organs from deceased donors are automatically allocated through the China Organ Transplant Response System in accordance with national policies ( 17 ) . None of the patients in this study received liver grafts from prisoners. All HCC transplant patients met the Hangzhou criteria ( 17 ) . After excluding pediatric LT, re-transplantation, multi-organ transplantation, living donor transplantation, and incomplete data, 5419 adult WLT and 559 adult SLT patients were enrolled in this study. Among these, 2308 patients with HCC and 3111 patients with non-HCC ESLD received WLT, while 214 HCC and 345 non-HCC ESLD patients underwent SLT. For the purpose of this study, SLT recipients were matched with WLT recipients using PSM at a 1:1 ratio. Matching criteria included age, sex, year of operation, MELD score, donor type, donor and recipient BMI, primary disease, CIT, WIT, operation time, and other relevant factors. After PSM, the characteristics of 536 SLT recipients were compared with those of 536 WLT recipients ( Fig. 1 ) . The study has been reported in line with the STROCSS criteria ( 18 ) . Technical Specifications China's split liver transplantation (SLT) protocols systematically integrate anatomical optimization and ischemia mitigation strategies. Donor selection follows stringent biological criteria:(1)Normal hepatic function (ALT < 40 U/L, AST 30% macrosteatosis exclusion)(3)Anatomical integrity confirmed by triphasic CT/MR cholangiography.In adult SLT, two primary liver splitting techniques are commonly used: (1)Full Left-Right Graft Partitioning:The parenchymal transection plane follows the principal portal fissure (Cantlie line), preserving:① Right graft: Hepatic artery segment IV branch, right portal vein (≥ 8 mm diameter), and sectoral bile ducts (Couinaud segments V-VIII),②Left graft: Left hepatic vein trunk (≥ 5 mm) and segment II/III biliary confluence Right grafts target recipients with BMI > 25, while left grafts serve BMI < 22 adults.(2)Right Trisection Graft Preparation:The division plane extends along the right hepatic vein, creating:① Trisection graft: Segments IV-VIII with intact middle hepatic vein reconstructed via interposition grafts②Left lateral graft: Segments II-III with preserved umbilical fissure vasculature.This technique achieves 1.2% hepatic artery thrombosis rate through microsurgical anastomosis (8 − 0 polypropylene) under 3.5× loupe magnification. Both approaches mandate sequential vascular clamping (total ischemia < 45 min) and real-time indocyanine green perfusion testing to validate biliary-vascular patency. Graft selection prioritizes portal flow symmetry (Doppler-verified flow velocity differential < 15 cm/s) and recipient anthropometrics (graft-to-recipient weight ratio ≥ 0.8%). Data collection We collected clinical information prior to LT, including age, sex, operation year, MELD score, type of donor, donor and recipient BMI, primary disease, and other relevant factors. Additionally, intraoperative data such as CIT, WIT, and operation time were also gathered. Postoperative complications within 90 days of hospitalization were documented, including intra-abdominal bleeding, new-onset hypertension, newly diagnosed diabetes, graft-versus-host disease (GVHD), bile duct complications, vascular complications, early allograft dysfunction(EAD), pleural effusion, pulmonary edema, acute kidney injury(AKI), and postoperative infection. It should be noted that patients who received a right half liver graft were transplanted with segments S5-8, while those who received a right tri-segment graft were transplanted with segments S4-8. The selection of the donor liver was based on a comprehensive evaluation that included the donor liver size and GRWR, the recipient's liver function status, donor vascular anatomy, surgical complexity, and the associated risk of complications. Vascular complications included anastomotic stenosis, torsion, and thrombosis, while bile duct complications encompassed anastomotic stenosis, torsion, and bile leakage. The primary endpoints of this analysis were patient death or tumor recurrence. All complications were thoroughly documented during the patient's hospitalization. Statistical Analysis The statistical analysis was performed using the statistical software SAS, version 9.4 software (SAS Institute Inc). Quantitative variables are expressed as the mean ± standard deviation or median and range depending on the distribution. Categorical variables are presented as values and percentages. Student t-test or nonparametric test were used to compare quantitative variables with or without a bell-shaped distribution. Chi-square test was used to compare categorical variables. OS and DFS were calculated using the Kaplan–Meier method. For survival analysis, a log-rank test was used to assess group difference. To identify risk factors for OS, a multivariate analysis was performed. The Odds Ratio (OR) and its 95% confidence interval (CI) were estimated in the univariable and multivariable logistic regression analyses. All tests were two-sided, with a P value of < 0.05 considered statistically significant. RESULTS Baseline characteristics and outcomes After propensity score matching (PSM), 536 liver transplant recipients were included in the comparative analysis. Pre-PSM analysis revealed significant intergroup disparities in sex distribution (female: 65.7% vs 80.8%, P < 0.0001), biological parameters (MELD score: 24.4 vs 26.9; BMI: 22.0 vs 23.4 kg/m²), and operative characteristics (WIT: 3.3 vs 5.1 min; GRWR: 1.5 vs 2.1; all P 0.05), with the exception of persistently lower GRWR in SLT recipients 1.5 vs2.4, P < 0.0001). During the median follow-up of 18.5 months (mean 22.4 months), SLT demonstrated comparable safety profiles to WLT regarding metabolic complications (new-onset diabetes: 9.9% vs 12.9%; hypertension: 1.7% vs 2.8%) and organ-specific sequelae (pleural effusion: 17% vs 16%; pulmonary edema: 0.4% vs 0%; all P > 0.05). However, SLT was associated with elevated risks of immediate postoperative morbidity:(1)Intra acute bleeding (6.7% vs 3.2%, P < 0.05)(2)Biliary complications (3.9% vs 1.9%, P < 0.05)(3)Vascular complications (3.9% vs 1.1%, P < 0.05).Notably, critical endpoints including early allograft dysfunction (EAD: 13.1% vs 11.4%), graft-versus-host disease (GVHD: 2.3% vs 1.7%), and systemic infections (18.9% vs 16.3%) showed no statistical intergroup divergence (all P > 0.05) (Table S1 ) . ‌Matched cohort analysis in HCC patients of WLT and SLT Following 1:1 PSM of 202 SLT and 202 WLT recipients with hepatocellular carcinoma, baseline comparability was achieved for oncological parameters (tumor number, maximum diameter), demographic characteristics (age, sex, MELD score), and perioperative metrics (CIT, WIT, ABO mismatch ratio; all P > 0.05). Two critical disparities persisted in the SLT cohort:(1)Significantly reduced hemoglobin levels (69.2 vs 104.9 g/L, P < 0.0001)(2)Lower median graft-to-recipient weight ratio (1.4% vs 2.1%, P < 0.001).Postoperative analysis revealed SLT-specific morbidity patterns:(1)increased risk of early allograft dysfunction (EAD: 25.7% vs 16.8%, P < 0.0001 );(2)higher incidence of pleural effusion (17.3% vs 9.9%, P < 0.0001) Notably, other surgical complications including biliary complications (3.5% vs 2.0%), vascular thrombosis (3.0% vs 1.0%), and systemic infections (13.4% vs 11.4%) demonstrated comparable rates between cohorts (all P > 0.05) ( Table 1 ). Table 1 HCC recipient characteristics of enrolled cohort HCC recipients Before PSM After PSM SLT(n = 214) WLT(n = 2308) P -value SLT(n = 202) WLT(n = 202) P -value Preoperative baseline characteristics Female, n 168 2073 < 0.0001 163 158 0.5381 Age, mean (± SD) 53.1(± 9.4) 53.6(± 9.3) < 0.4930 53.1(± 9.4) 52.7(± 9.6) 0.6363 Operation year < 0.0001 0.8295 2018 71 309 18 16 2019 60 323 29 31 2020 36 447 35 31 2021 29 607 54 48 2.2022.1-2022.12 18 622 66 76 MELD score, mean(± SD) 21.0(± 12.7) 22.9(± 12.8) 0.0396 21.2(± 12.8) 21.0(± 12.9) 0.9166 Tumor classification Fulfilling Milan criteria,n(%) 88(41.1%) 971(42.1%) 0.5750 82(40.6%) 91(45.0%) 0.5058 Exceeding Milan but fulfilling Hang zhou(%) 40(18.7%) 368(15.9%) 0.5660 40(19.8%) 32(15.8%) 0.5870 Exceeding Hangzhou(%) 86(40.2%) 969(42.0%) 0.5768 80(39.6%) 79(39.1%) 0.5532 Number of tumors, n 0.2002 0.5860 1 103 1203 124 117 2–3 53 454 18 24 >3 58 651 60 61 AFP, n 0.1493 0.0989 ≤ 100 132 1471 97 113 100–400 19 276 51 34 ≥ 400 63 561 54 55 The biggest tumor diameter(cm),n 0.5495 0.1360 ≤ 3 98 954 89 102 4–5 43 543 42 47 6–7 27 283 25 25 ≥ 8 46 528 46 28 Albumin,mean (± SD) 34.5(± 6.2) 34.5(± 7.7) 0.9965 34.3(± 6.3) 35.0(± 6.6) 0.2984 ALT,mean (± SD) 137.2(± 578.1) 113.0(± 427.2) 0.6001 145.4(± 599.3) 85.8(± 235.8) 0.2523 AST,mean (± SD) 194.4(± 624.2) 188.9(± 689.2) 0.9210 206.3(± 646.6) 181.3(± 707.5) 0.7510 Total Bilirubin,mean (± SD) 157.9(± 185.4) 195.3(± 1168.4) 0.1718 158.0(± 186.0) 142.7(± 167.1) 0.3851 Hemoglobin,mean (± SD) 70.1(± 52.0) 100(± 53.1) < 0.0001 69.2(± 52.2) 104.9(± 38.5) < 0.0001 Type of Donor < 0.001 0.0535 DBD 124 825 117 106 DCD 55 952 52 73 DBCD 35 531 33 23 Recipients’ BMI,median(IQR) 22.8(20.6–24.5) 23.6(21.6–25.8) < 0.0001 22.9(20.7–24.5) 22.6(20.8–24.2) 0.6075 Donors’ BMI, median (IQR) 23.4(21.8–25.1) 23.4(21.5–25.4) 0.4150 23.4(21.7–24.8) 23.2(21.2–25.4) 0.9594 Per operative data CIT(h), mean (± SD) 5.5(± 2.7) 6.0(± 2.9) 0.0240 5.5(± 2.7) 5.7(± 2.8) 0.9478 WIT (min), mean (± SD) 40(± 7.2) 52(± 7.2) 0.0142 41(± 7.4) 38(± 6.4) 0.6661 Operation time(h), mean (± SD) 7.3(± 2.1) 6.6(± 1.7) < 0.0001 7.2(± 2.0) 7.1(± 1.9) 0.5087 ABO-incompatible, n(%) 5(3.0%) 69(3.3%) 0.5881 5(2.5%) 2(1.0%) 0.2527 GRWR(%), median(IQR) 1.4(1.2–1.7) 2.1(1.8–2.5) < 0.0001 1.4(1.2–1.7) 2.1(1.8–2.6) < 0.0001 Classification of split donor liver, n Left half liver 39 31 Right half or right tri-segment liver 175 171 Postoperative complications Intra-Abdominal Bleeding, n(%) 10(4.7%) 85(3.7%) 0.4580 9(4.5%) 5(2.5%) 0.2724 Biliary Complications, n(%) 8(3.7%) 49(2.1%) 0.1251 7(3.5%) 4(2.0%) 0.3547 Vascular Complication, n(%) 6(2.8%) 20(0.9%) 0.0070 6(3.0%) 2(1.0%) 0.1511 EAD, n(%) 55(25.7%) 427(18.5%) 0.0104 52(25.7%) 34(16.8%) 0.0287 New-onset Diabetes Mellitus, n(%) 19(8.9%) 313(13.6%) 0.0550 18(9.0%) 21(10.4%) 0.6247 New-onset Hypertension, n(%) 4(1.9%) 84(3.6%) 0.1802 3(1.5%) 6(3.0%) 0.3155 Pleural Effusion, n(%) 38(17.8%) 347(15.0%) 0.2761 35(17.3%) 20(9.9%) 0.0281 Pulmonary Edema, n(%) 1(0.5%) 0(0) 0.0009 1(0.5%) 0(0) 0.3143 GVHD, n(%) 0(0) 0(0) 0(0) 0(0) AKI,n(%) 54(25.2%) 492(21.3%) 0.1833 50(24.8%) 63(31.2%) 0.1496 Infection Pulmonary infection, n(%) 28(13.1%) 347(15.0%) 0.4570 27(13.4%) 23(11.4%) 0.5455 Catheter Sepsis, n(%) 1(0.5%) 4(0.2%) 0.3530 1(0.5%) 0(0) 0.3155 Urinary Tract Infection, n(%) 0(0) 4(0.2%) 0.5431 0(0) 0(0) Wound Infection, n(%) 4(1.9%) 13(0.6%) 0.0251 4(2.0%) 1(0.5%) 0.1752 CIT, cold ischemia time; WIT, warm ischemia time; BMI, body mass index; LT, liver transplant; MELD, Model for End-stage Liver Disease; GRWR,graft-to-recipient weight ratio; HCC, hepatocellular carcinoma;EAD, early allograft dysfunction; PTLD, posttransplant lymphoproliferative disorders; GVHD, graft-versus-host disease; AKI, acute kidney injury. ‌Matched cohort analysis in Non-HCC ESLD patients of WLT and SLT Through 1:1 propensity score matching of 318 SLT and 318 WLT recipients with non-HCC ESLD, balanced baseline characteristics were achieved for disease etiology (primary diagnosis distribution), transplant parameters (CIT: 5.8 vs 5.5 hr; WIT: 31 vs 32 min), and operative profiles (operation time: 7.3 vs 7.2 hr; all P > 0.05). Two clinically relevant intergroup disparities persisted:(1)Lower pre-transplant hemoglobin in SLT cohort (53.9 vs 74.9g/L,P < 0.0001)(2)Reduced graft adequacy(GRWR: 1.5% vs 2.5%, P < 0.001).Postoperative analysis demonstrated distinct complication profiles compared to WLT group:(1)increased risk of intra-abdominal bleeding (13.5% vs 8.5%, P < 0.05);(2)higher vascular complications (4.7% vs 1.9%, P < 0.05). Notably, this complication pattern diverged from HCC patients who exhibited higher EAD risk. Critical endpoints including biliary complications (14% vs 6.0%), pleural effusion (17.3% vs 16.4%) remained comparable between cohorts (all P > 0.05) ( Table 2 ) . Table 2 Non-HCC recipient characteristics of enrolled cohort Non-HCC recipients Before PSM After PSM SLT(n = 345) WLT(n = 3111) P -value SLT(n = 318) WLT(n = 318) P -value Preoperative baseline characteristics Primary diagnosis Decompensation of cirrhosis,n(%) 232(67.2%) 1583(50.9%) < 0.0001 210(66.0%) 202(63.5%) 0.5066 Liver failure,n(%) 84(24.3%) 926(29.8%) 0.0358 81(25.5%) 78(24.5%) 0.7835 Metabolic disease,n(%) 9(2.6%) 25(0.8%) 0.0013 4(1.3%) 9(2.8%) 0.1612 Others,n(%) 13(3.8%) 50(1.6%) 0.0044 11(3.5%) 7(2.2%) 0.3388 Female, n 199 2304 < 0.0001 127 136 0.4687 Age, mean (± SD) 51.6(± 11.7) 49.6(± 10.8) 0.0028 51.3(± 11.6) 50.8(± 10.8) 0.5394 Operation year < 0.0001 0.0108 2018 23 765 23 32 2019 33 717 32 48 2020 72 513 69 50 2021 112 509 97 72 2022.1-2022.12 105 607 97 116 MELD score, mean(± SD) 26.6(± 11.3) 29.9(± 10.0) < 0.0001 27.2(± 11.2) 27.4(± 10.8) 0.8235 Albumin,mean (± SD) 32.9(± 6.6) 32.9(± 9.2) 0.9738 33.0(± 6.8) 33.6(± 14.2) 0.4914 ALT,mean (± SD) 93.9(± 329.4) 129.8(± 425.2) 0.1346 100.2(± 346.4) 124.4(± 393.0) 0.5143 AST,mean (± SD) 117.7(± 302.8) 176.5(± 705.0) 0.0279 125.5(± 318.1) 151.8(± 477.2) 0.5259 Total Bilirubin,mean (± SD) 240.8(± 206.6) 287.3(± 201.1) < 0.0001 251.1(± 208.5) 252.2(± 197.4) 0.9449 Hemoglobin,mean (± SD) 55.7(± 42.4) 75.0(± 46.4) < 0.0001 53.9(± 42.2) 74.9(± 38.3) < 0.0001 Type of Donor < 0.0001 0.3745 DBD 211 1244 192 188 DCD 84 1194 77 90 DBCD 50 673 49 40 Recipients’ BMI, median(IQR) 21.5(19.1–23.4) 23.1(21.0-25.4) < 0.0001 21.6(19.4–23.5) 21.5(19.5–23.6) 0.7713 Donors’ BMI, median(IQR) 23.6(21.6–25.7) 23.4(21.4–25.4) 0.0472 23.6(21.6–25.6) 23.4(21.2–26.0) 0.7536 Per operative data CIT(h), mean (± SD) 5.8(± 2.8) 6.0(± 3.1) 0.1187 5.8(± 2.8) 5.5(± 3.0) 0.2043 WIT(min), mean (± SD) 29(± 5.5) 51(± 7.0) < 0.0001 31(± 5.7) 32(± 5.5) 0.8305 Operation time(h), mean (± SD) 7.5(± 2.2) 6.6(± 1.7) < 0.0001 7.3(± 2.1) 7.2(± 2.2) 0.6054 ABO-incompatible, n(%) 9(2.6%) 178(5.7%) 0.0153 9(2.6%) 9(2.6%) 1 GRWR(%), median(IQR) 1.6(1.2–1.9) 2.1(1.8–2.5) < 0.0001 1.5(1.2–1.9) 2.5(2.1-3.0) < 0.0001 Classification of split donor liver,n Left half liver 73 66 Right half or right tri-segment liver 272 252 Postoperative complications Intra-Abdominal Bleeding, n(%) 27(7.8%) 153(4.9%) 0.0214 27(8.5%) 11(3.5%) 0.0074 Biliary Complications, n(%) 15(4.3%) 71(2.3%) 0.0197 14(4.4%) 6(1.9%) 0.0691 Vascular Complication, n(%) 16(4.6%) 37(1.2%) < 0.0001 15(4.7%) 6(1.9%) 0.0458 EAD, n(%) 95(27.5%) 676(21.7%) 0.0140 89(28.0%) 68(21.4%) 0.0535 New-onset Diabetes Mellitus, n(%) 39(11.3%) 441(14.2%) 0.1400 35(11.0%) 44(13.8%) 0.2792 New-onset Hypertension, n(%) 8(2.3%) 84(2.7%) 0.6725 7(2.2%) 4(1.3%) 0.3643 Pleural Effusion, n(%) 59(17.1%) 519(16.7%) 0.8533 55(17.3%) 52(16.4%) 0.7505 Pulmonary Edema, n(%) 1(0.3%) 8(0.3%) 0.9095 1(0.3%) 1(0.3%) 1 GVHD, n(%) 1(0.3%) 2(0.1%) 0.2510 1(0.3%) 0(0) 0.2830 AKI,n(%) 106(30.7%) 787(25.3%) 0.0289 100(31.4%) 81(25.5%) 0.0950 Infection Pulmonary infection, n (%) 65(18.8%) 578(18.6%) 0.9166 59(18.6%) 58(18.2%) 0.9185 Catheter Sepsis, n (%) 1(0.3%) 3(0.1%) 0.3169 1(0.3%) 1(0.3%) 1 Urinary Tract Infection, n (%) 1(0.3%) 3(0.1%) 0.3169 1(0.3%) 0(0) 0.3169 Wound Infection, n (%) 2(0.6%) 33(1.1%) 0.3980 2(0.6%) 4(1.3%) 0.4142 CIT, cold ischemia time; WIT, warm ischemia time; BMI, body mass index; LT, liver transplant; MELD, Model for End-stage Liver Disease; GRWR,graft-to-recipient weight ratio; HCC, hepatocellular carcinoma;EAD, early allograft dysfunction; PTLD, posttransplant lymphoproliferative disorders; GVHD, graft-versus-host disease; AKI, acute kidney injury Overall Survival Comparative survival analysis revealed differential outcomes before and after PSM. In the pre-matched cohort, WLT recipients demonstrated nominally superior OS rates compared to SLT counterparts, with 1-, 3-, and 5-year OS of 85.3% vs 79.1%, 75.0% vs 71.0%, and 68.7% vs 66.2% respectively (log-rank P = 0.003). However, this survival disparity was attenuated following 1:1 PSM, where comparable OS outcomes emerged between matched cohorts (WLT: 83.0%, 74.4%, 61.8% vs SLT: 78.8%, 70.5%, 65.8%; log-rank P = 0.159) (eFigure1). The study cohort was stratified into HCC and non-HCC ESLD subgroups. In the HCC cohort prior to propensity score matching (PSM), comparable overall survival (OS) was observed between split liver transplantation (SLT) and whole liver transplantation (WLT) recipients (P = 0.350, eFigure2A). Following 1:1 PSM (n = 202 per group), Kaplan-Meier analysis demonstrated no statistically significant differences in post-transplant outcomes between matched cohorts. The SLT group exhibited 1-, 3-, and 5-year OS rates of 78.8%, 70.5%, and 65.8% respectively, compared with 83.0%, 74.4%, and 61.8% in the WLT group (log-rank P = 0.088). Disease-free survival (DFS) rates were similarly comparable between groups (74.3%, 64.7%, 61.9% vs 81.0%, 70.8%, 60.7%; log-rank P = 0.111) (Fig. 2 A-B). Subgroup analysis of HCC recipients based on tumor burden criteria revealed comparable survival outcomes across three distinct categories: those fulfilling Milan criteria, those exceeding Milan but fulfilling Hangzhou criteria, and those surpassing Hangzhou criteria (Fig. 2 C-E). Surgical approach analysis demonstrated equivalent prognostic outcomes between SLT recipients receiving left hemiliver grafts versus right trisegment grafts. Notably, post-PSM analysis revealed no significant disparity in tumor recurrence patterns between SLT and WLT cohorts, with 1- and 3-year recurrence rates of 10.3% vs 15.1% (P = 0.604) and 16.3% vs 15.4% respectively (eFigure 2B). For non-HCC patients,pre-PSM Analysis‌: Whole liver transplantation (WLT; n = 3,111) demonstrated significantly higher overall survival (OS) rates compared to split liver transplantation (SLT; n = 345) before propensity score matching (PSM). Kaplan-Meier estimates revealed 1-, 3-, and 5-year OS rates of 84.3%, 80.0%, and 76.3% for WLT versus 79.1%, 74.2%, and 65.9% for SLT, respectively (log-rank P = 0.015; Fig. 1 A);Post-PSM Comparison‌: After 1:1 PSM (WLT: n = 318; SLT: n = 318), the survival advantage of WLT was attenuated, with no statistically significant difference observed between matched groups (1-/3-/5-year OS: 84.0%/79.2%/76.1% vs. 78.2%/72.8%/64.0%; P = 0.074; Fig. 3 B); SLT Graft-Type Subanalysis‌: Among post-PSM SLT recipients, those receiving right hemi-liver or right tri-segment grafts (n = 255) exhibited markedly superior prognosis compared to left hemi-liver graft recipients (n = 66). The 1- and 3-year OS rates were 82.2% vs. 63.4% and 77.2% vs. 57.8%, respectively (log-rank P < 0.001; Fig. 3 C). Risk factors for Overall Survival To delineate prognostic determinants of post-transplant survival, we performed comprehensive risk stratification through sequential univariable and multivariable analyses in HCC and non-HCC cohorts. Variables achieving statistical significance (P < 0.05) in univariable screening were subjected to multivariable Cox proportional hazards regression. For ‌HCC recipients‌,multivariable modeling identified six independent predictors of reduced OS):(1)Elevated donor body mass index (BMI: HR = 1.039 per kg/m², 95% CI 1.016–1.063, P = 0.001);(2)Recipient BMI (HR = 0.965 per kg/m², 95% CI 0.942–0.990, P 25 (HR = 1.574, 95% CI 1.336–1.854, P < 0.001); (4)Prolonged cold ischemia time (CIT: HR = 1.101 per hour, 95% CI 1.072–1.131, P < 0.001); (5)Tumors exceeding Milan criteria while meeting Hangzhou criteria (HR = 1.718, 95% CI 1.308–2.257, P < 0.001);(6)Tumors surpassing Hangzhou criteria (HR = 3.291, 95% CI 2.701–4.011, P < 0.001). For ‌Non-HCC recipients,‌three factors independently predicted inferior OS:(1)Advanced recipient age (HR = 1.026 per year, 95% CI 1.017–1.034, P = 0.001);(2)Extended CIT duration (HR = 1.070 per hour, 95% CI 1.042-1.100, P < 0.001);(3)SLT(vs. WLT: HR = 1.555, 95% CI 1.209-2.000, P = 0.001).Notably, comprehensive evaluation of donor characteristics (vascular anatomy, graft quality) and recipient anatomical factors demonstrated no significant associations with OS in either cohort through univariable analysis ( Table 3 ) . Table 3 Univariable and Multivariable analysis of risk factors for OS Pre-translplant risk factor for OS Univariable Multivariable HR IC95% P-value HR IC95% P-value HCC Donors’ age 1.005 0.999–1.011 0.096 Donors’ BMI 1.036 1.012–1.060 0.003 1.039 1.016–1.063 0.001 Recipients’ age 1.005 0.996–1.014 0.261 Recipients’ BMI 0.961 0.938–0.985 0.002 0.965 0.942–0.990 25 1.714 1.457–2.016 0.000 1.574 1.336–1.854 < 0.001 CIT 1.104 1.076–1.133 0.000 1.101 1.072–1.131 < 0.001 WLT / SLT 1.193 0.887–1.603 0.350 Fulfilling Milan(baseline) Exceeding Milan but fulfilling Hang zhou 1.764 1.343–2.317 0.000 1.718 1.308–2.257 < 0.001 Exceeding Hangzhou 3.359 2.757–4.092 0.000 3.291 2.701–4.011 < 0.001 Non-HCC Donors’ age 1.002 0.999–1.005 0.300 Donors’ BMI 0.985 0.961–1.010 0.228 Recipients’ age 1.024 1.016–1.033 0.000 1.026 1.017–1.034 25 1.080 0.903–1.292 0.400 CIT 1.084 1.055–1.113 0.000 1.070 1.042-1.100 < 0.001 SLT/WLT 1.438 1.120–1.847 0.015 1.555 1.209-2.000 0.001 CIT, cold ischemia time; BMI, body mass index; MELD, Model for End-stage Liver Disease. DISCUSSION Herein, we present the world's largest multicenter sample analyzing the outcomes of adult liver transplantation patients, with a focus on the application of SLT in this population. Our findings underscore the non-inferiority of SLT versus WLT in terms of OS among adult recipients (P > 0.05), highlighting its potential as a viable strategy to address the persistent organ shortage.Despite the uncertainty surrounding the progression of hepatocellular carcinoma (HCC), up to 30% of HCC patients awaiting transplantation may develop contraindications due to tumor progression ( 19 ) . The topic of partial liver transplantation for HCC has long been a subject of significant scholarly interest and discussion. A study conducted by 81 transplant centers in China concluded that there was no statistically significant difference in OS and DFS between LDLT and WLT in HCC patients. ( 20 ) Similarly, a study from the United States found no statistical difference in graft survival curves between SLT and WLT in HCC patients ( 21 ) . Our study, in line with previous research, found no statistically significant difference in OS and DFS between SLT and WLT in HCC patients (P > 0.05). Further validating our results, we observed comparable tumor recurrence rates between the two groups (1-year and 3-year recurrence rates: 10.3% and 16.3% vs 11.6% and 29.0%, respectively; P = 0.576). These findings suggest that SLT is a safe and effective option for adult HCC patients, particularly under rigorous oncological surveillance and stringent selection criteria.In non-HCC ESLD patients, while we did not observe a statistically significant difference in OS between SLT and WLT PSM, a notable difference emerged in the type of graft received. Specifically, recipients of right hemiliver or right trisegment grafts demonstrated superior long-term survival compared to those receiving left hemiliver grafts (1-year OS: 82.2% vs. 63.4%; 3-year OS: 77.2% vs. 57.8%, P < 0.001). This finding highlights the importance of graft-type optimization in maximizing the outcomes of SLT in non-HCC ESLD patients. The implementation of SLT in non-HCC ESLD patients presents persistent challenges requiring multidisciplinary coordination among transplant teams, meticulous evaluation of donor-recipient compatibility, and precise execution of technically demanding procedures including vascular/biliary segmentation and graft reconstruction ( 22 ) . Our propensity-matched analysis revealed distinct complication profiles, with SLT recipients exhibiting significantly higher rates of intra-abdominal bleeding (13.5% vs 8.5%,P < 0.05) and vascular complications (4.7% vs 1.9%,P < 0.05 )in adult non-HCC ESLD patients. These disparities may stem from the compounded effects of:(1)Impaired hepatic functional reserve in ESLD patients limiting regenerative capacity;(2)Immunosuppression-mediated interference with post-operative healing;(3)Anatomical complexity inherent to partial-graft vascular anastomoses.Notably, the vascular complication rate aligns with prior reports of 11–15% in SLT/LDLT series ( 23 – 25 ) , with graft configuration emerging as a critical determinant. Right-sided grafts demonstrated superior outcomes (3-year OS: 77.2% vs 57.8% for left grafts), suggesting surgical approach optimization may mitigate risks. The basic definition of EAD is that in the early stage after liver transplantation, the graft function is in a marginal state ( 26 ) . Our analysis also revealed significantly elevated risks of EAD and pleural effusion in adult HCC patients receiving SLT compared to WLT recipients (‌EAD: 25.7% vs 16.8%, P < 0.001; pleural effusion: 17.3% vs 9.9%, P < 0.001‌). Some EAD can progress to cause graft dysfunction, leading to death or re-transplantation, which is one of the most serious complications after liver transplantation.Similarly, a study from the United Kingdom also reported that the incidence of early liver failure was higher in SLT recipients using DBD-derived donors and extended right half liver grafts compared to recipients of WLT from DCD donors (2 7 ) . Mechanistically, EAD may be precipitated by:Insufficient graft mass (SLT 1.4%vsWLT 2.1,P < 0.001),preoperative hemoglobin of patients(SLT 69.2g/LvsWLT 104.9g/L mean,P < 0.001),ABO-incompatible. Through comprehensive univariable and multivariable analyses, we identified several independent risk factors for OS in both HCC and non-HCC recipients. For HCC patients, these included donor body mass index (BMI), recipient BMI, Model for End-Stage Liver Disease (MELD) score > 25, cold ischemia time (CIT), and exceeding Milan/Hangzhou criteria. In non-HCC recipients, age, CIT, and the type of transplantation (SLT vs. WLT) were independent predictors of mortality.The increase of donor BMI may be accompanied by liver steatosis, which increases the risk of primary graft nonfunction, especially in SLT, the functional reserve after fatty liver segmentation is further reduced. High BMI recipients are more likely to induce insulin resistance and dyslipidemia due to immunosuppressants, accelerate atherosclerosis, and lead to cardiovascular disease related death. CIT was identified as an independent risk factor for OS in both HCC and non HCC patients, which was consistent with many studies. Prolonged CIT can lead to ischemia-reperfusion injury. At the same time, in SLT, the segmentation process may further prolong CIT, especially in vitro splitting operation. High MELD scores are often associated with coagulation disorders and systemic inflammation, which increase the risk of intraoperative bleeding and postoperative sepsis. Age as a risk factor in non HCC patients may reflect the impact of coexisting diseases (such as cardiovascular disease and renal insufficiency) on surgical tolerance. Elderly patients are more prone to infection after operation. SLT is an independent risk factor in non-HCC ESLD patients, but not in HCC patients. This fact proved SLT is a safe and reliable option for adult HCC recipient.Despite SLT being identified as an independent risk factor for long-term survival in non-HCC patients (HR = 1.555, 95% CI 1.209-2.000,p < 0.05), our study revealed superior survival outcomes in recipients of right hemiliver and right trisegment grafts compared to left hemiliver grafts(3-year OS: 77.2% vs 57.8%, P < 0.001) While our study provides valuable insights into the outcomes of SLT in adult liver transplantation, it is not without limitations. As a retrospective study, it is susceptible to reporting biases and reflects the specific perioperative management strategies adopted by the participating transplant centers. Furthermore, the presented data may not be generalizable to transplant centers in other countries with different allocation rules and recipient selection policies. In conclusion, our findings support the adoption of SLT as a safe and reliable option for adult HCC patients, offering equivalent long-term survival outcomes to WLT. For non-HCC ESLD patients, optimization of graft type, with a preference for right-sided grafts, combined with minimization of CIT and stringent recipient selection, may maximize the benefits of SLT. Future studies with larger sample sizes and multicenter collaborations are warranted to further validate our findings and guide clinical practice in this area. Abbreviations HCC hepatocellular carcinoma Non-HCC non hepatocellular carcinoma ESLD end stage liver disease LT liver transplantation SLT split liver transplantation WLT whole liver transplantation PSM propensity score matching MELD model for end-stage liver disease AFP alpha fetoprotein GVHD graft versus host disease EAD early allograft dysfunction OS overall survival DFS disease-free survival Declarations ACKNOWLEDGMENTS: This work was supported by grants from National Key Research and Development Program of China (2021YFA1100500), National Natural Science Foundation of China (92159202) and Key Research & Development Plan of Zhejiang Province (2022C03108). CONFLICT OF INTEREST STATEMENT: The authors declare no conflicts of interest. ETHICS STATEMENT: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This was performed according to the Declaration of Helsinki and approved by the CLTR (No. 20230030). Informed consent: Informed consent was obtained from all the patients for the use of their data for research purposes. No organs from executed prisoners were used. Registry and the Registration No. of the study/trial: N/A. Animal studies: N/A. Author Contribution We, the undersigned authors, certify that each author has contributed significantly to the work and takes public responsibility for appropriate portions of the content. Specifically, the contributions are as follows:‌Yunguo Lei‌ and ‌Jun Pan‌ (co-first authors): Designed the study, analyzed the data, and drafted the manuscript.‌Zhe Yang‌ (co-first author): Participated in data analysis and manuscript preparation.‌Jun Chen‌: Provided critical revisions and intellectual input to the manuscript.‌Beng Yang‌: Assisted in data interpretation and manuscript editing.‌Zhisheng Zhou‌: Contributed to the data collection and analysis.‌Shengjun Xu‌: Provided intellectual input and critical revisions.‌Kai Wang‌: Assisted in data interpretation and manuscript preparation.‌Ronggao Chen‌: Participated in the study design and data collection.‌Jinzhen Cai‌: Contributed to data analysis and interpretation.‌Shusen Zheng‌: Provided intellectual input and critical revisions.‌Qiang Wei‌ and ‌Xiao Xu‌ (co-corresponding authors): Supervised the study, contributed to the study design, data interpretation, and critical revisions of the manuscript.All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work. References Goldaracena N, Echeverri J, Kehar M, DeAngelis M, Jones N, Ling S, et al. Pediatric living donor liver transplantation with large-for-size left lateral segment grafts. Am J Transplant. 2020;20(2):504–12. Samuel D, De Martin E, Berg T, Berenguer M, Burra P, Fondevila C, et al. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81(6):1040–86. Busuttil RW, Goss JA. Split liver transplantation. Ann Surg. 1999;229(3):313–21. Azoulay D, Castaing D, Adam R, Savier E, Delvart V, Karam V, et al. Split-liver transplantation for two adult recipients: feasibility and long-term outcomes. Ann Surg. 2001;233(4):565–74. Hackl C, Schmidt KM, Susal C, Dohler B, Zidek M, Schlitt HJ. Split liver transplantation: Current developments. World J Gastroenterol. 2018;24(47):5312–21. Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am J Transplant. 2023;23(2 Suppl 1):S178-S263. Angelico R, Nardi A, Adam R, Nadalin S, Polak WG, Karam V, et al. Outcomes of left split graft transplantation in Europe: report from the European Liver Transplant Registry. Transpl Int. 2018;31(7):739–50. Sasaki K, Firl DJ, McVey JC, Schold JD, Iuppa G, Diago Uso T, et al. Elevated Risk of Split-Liver grafts in adult liver Transplantation: Statistical Artifact or Nature of the Beast? Liver Transpl. 2019;25(5):741–51. Hashimoto K, Fujiki M, Quintini C, Aucejo FN, Uso TD, Kelly DM, et al. Split liver transplantation in adults. World J Gastroenterol. 2016;22(33):7500–6. Gavriilidis P, Roberts KJ, Azoulay D. Right lobe split liver graft versus whole liver transplantation: A systematic review by updated traditional and cumulative meta-analysis. Dig Liver Dis. 2018;50(12):1274–82. Ross MW, Cescon M, Angelico R, Andorno E, Rossi G, Pinna A, et al. A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts. Liver Transpl. 2017;23(11):1384–95. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6(4):783–90. Moussaoui D, Toso C, Nowacka A, McLin VA, Bednarkiewicz M, Andres A, et al. Early complications after liver transplantation in children and adults: Are split grafts equal to each other and equal to whole livers? Pediatr Transplant. 2017;21(4). Wan P, Li Q, Zhang J, Xia Q. Right lobe split liver transplantation versus whole liver transplantation in adult recipients: A systematic review and meta-analysis. Liver Transpl. 2015;21(7):928–43. Zhang L, Zeng L, Gao X, Wang H, Zhu Y. Transformation of organ donation in China. Transpl Int. 2015;28(4):410–5. Benedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg. 2018;53(6):1112–7. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726–32. Mathew G, Agha R, Albrecht J, Goel P, Mukherjee I, Pai P, et al. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2021;96:106165. Ogawa K, Takada Y. Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2016;1:35. Hu Z, Qian Z, Wu J, Zhou J, Zhang M, Zhou L, et al. Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation. Clin Res Hepatol Gastroenterol. 2016;40(3):315–26. Matsuoka LK, Sutcliffe T, Feurer ID, Rega SA, Ziogas IA, Izzy M, et al. Comparison of Survival Outcomes After Deceased Donor Split Versus Whole Liver Transplant for Hepatocellular Carcinoma. Exp Clin Transplant. 2021;19(8):811–6. Yao J, Lei YG, Yi HM, Yang Y. Clinical strategies to improve the survival rate of liver recipients with acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2023;22(1):41–4. Zhong J, Smith C, Walker P, Sheridan M, Guthrie A, Albazaz R. Imaging post liver transplantation part I: vascular complications. Clin Radiol. 2020;75(11):845–53. Duffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, et al. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg. 2009;208(5):896–903; discussion – 5. Khalaf H. Vascular complications after deceased and living donor liver transplantation: a single-center experience. Transplant Proc. 2010;42(3):865 – 70. Agopian VG, Harlander-Locke MP, Markovic D, Dumronggittigule W, Xia V, Kaldas FM, et al. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model. JAMA Surg. 2018;153(5):436–44. Mallik M, Callaghan CJ, Hope M, Gibbs P, Davies S, Gimson AE, et al. Comparison of liver transplantation outcomes from adult split liver and circulatory death donors. Br J Surg. 2012;99(6):839–47. Additional Declarations No competing interests reported. Supplementary Files SupplementaryMaterial2.zip Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6432057","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":449680414,"identity":"657542d7-629c-4326-8fc8-d991373f5c89","order_by":0,"name":"Yunguo Lei","email":"","orcid":"","institution":"Zhejiang University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Yunguo","middleName":"","lastName":"Lei","suffix":""},{"id":449680415,"identity":"db455c36-7917-4ee8-94a5-a0ea1352e08d","order_by":1,"name":"Jun Pan","email":"","orcid":"","institution":"Zhejiang University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Jun","middleName":"","lastName":"Pan","suffix":""},{"id":449680416,"identity":"9c422936-e9e7-42f0-aef9-8f321b391c7d","order_by":2,"name":"Zhe Yang","email":"","orcid":"","institution":"Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Zhe","middleName":"","lastName":"Yang","suffix":""},{"id":449680417,"identity":"15ac6f6c-6821-4487-a8d4-5fa5715f67c2","order_by":3,"name":"Jun Chen","email":"","orcid":"","institution":"Zhejiang Provincial People's Hospital，Affiliated People's Hospital, Hangzhou Medical College","correspondingAuthor":false,"prefix":"","firstName":"Jun","middleName":"","lastName":"Chen","suffix":""},{"id":449680418,"identity":"dd6b3aeb-b1a4-4e50-990a-65a3c3225943","order_by":4,"name":"Beng Yang","email":"","orcid":"","institution":"Zhejiang University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Beng","middleName":"","lastName":"Yang","suffix":""},{"id":449680419,"identity":"7443e50e-b442-4355-92a8-bc2d93ceb452","order_by":5,"name":"Zhisheng Zhou","email":"","orcid":"","institution":"National Center for Healthcare Quality Management of Liver Transplant","correspondingAuthor":false,"prefix":"","firstName":"Zhisheng","middleName":"","lastName":"Zhou","suffix":""},{"id":449680420,"identity":"8090cc77-63f7-40b4-a7f5-6ceb910a613a","order_by":6,"name":"Shengjun Xu","email":"","orcid":"","institution":"Zhejiang Provincial People's Hospital，Affiliated People's Hospital, Hangzhou Medical College","correspondingAuthor":false,"prefix":"","firstName":"Shengjun","middleName":"","lastName":"Xu","suffix":""},{"id":449680421,"identity":"7bb990e3-7e7c-4651-80f2-60e185b41f62","order_by":7,"name":"Kai Wang","email":"","orcid":"","institution":"Zhejiang Provincial People's Hospital，Affiliated People's Hospital, Hangzhou Medical College","correspondingAuthor":false,"prefix":"","firstName":"Kai","middleName":"","lastName":"Wang","suffix":""},{"id":449680422,"identity":"2d12572c-b1b0-4a91-a111-3026a560c10b","order_by":8,"name":"Ronggao Chen","email":"","orcid":"","institution":"Zhejiang University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Ronggao","middleName":"","lastName":"Chen","suffix":""},{"id":449680423,"identity":"fc1ab97c-af0b-492b-ab29-43efa52abd3a","order_by":9,"name":"Jinzhen Cai","email":"","orcid":"","institution":"Affiliated Hospital of Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"Jinzhen","middleName":"","lastName":"Cai","suffix":""},{"id":449680424,"identity":"642ab2be-78b9-45cb-93b3-94b5d19b5fe6","order_by":10,"name":"Shusen Zheng","email":"","orcid":"","institution":"Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Shusen","middleName":"","lastName":"Zheng","suffix":""},{"id":449680425,"identity":"f5c13d2d-a114-4b0f-8ddb-5c928bb2b717","order_by":11,"name":"Qiang Wei","email":"","orcid":"","institution":"Zhejiang University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Qiang","middleName":"","lastName":"Wei","suffix":""},{"id":449680426,"identity":"5882bec4-be2a-47f2-9963-00b358662622","order_by":12,"name":"Xiao Xu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAvElEQVRIiWNgGAWjYFCCAwwMHxjYQCwD4rUwziBRCwMDMw+EJlKLfOMZM2mbP3yJDezN2yQYau4Q1sLYcCxNOoeHLbGB51iZBMOxZ0Q4iuHwMekcCaAWiRwzCcaGw4S1sDEcbJO2MABqkX9DpBYekC0MCSBbeIjUAnR+smXPATbjNp60YouEY0RokZ9xxvDGjz/HZPvZD2+88aGGCC0MEgdA5DFIZCYQoYGBgb8BRNYQpXYUjIJRMApGKAAAUuAzszd3ebgAAAAASUVORK5CYII=","orcid":"","institution":"Zhejiang University School of Medicine","correspondingAuthor":true,"prefix":"","firstName":"Xiao","middleName":"","lastName":"Xu","suffix":""}],"badges":[],"createdAt":"2025-04-12 04:23:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6432057/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6432057/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":82002682,"identity":"1c557621-8353-47a2-a7e1-0720b941cbe3","added_by":"auto","created_at":"2025-05-05 20:21:44","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":683212,"visible":true,"origin":"","legend":"\u003cp\u003eSee image above for figure legend.\u003c/p\u003e","description":"","filename":"Figure1flow.png","url":"https://assets-eu.researchsquare.com/files/rs-6432057/v1/f637cfdb3728b006ab76e95c.png"},{"id":82002699,"identity":"9a6ac648-6b1c-429b-88d9-98e1c5ccc28f","added_by":"auto","created_at":"2025-05-05 20:21:51","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":3677624,"visible":true,"origin":"","legend":"\u003cp\u003eSee image above for figure legend.\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-6432057/v1/b2912bf367a51a50910d8795.png"},{"id":82002683,"identity":"6268ea7c-1de8-4260-86c7-ebd7a7e36a94","added_by":"auto","created_at":"2025-05-05 20:21:44","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":2308028,"visible":true,"origin":"","legend":"\u003cp\u003eSee image above for figure legend.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-6432057/v1/437e32f10e14497e68db4b5e.png"},{"id":86885623,"identity":"437b472c-d810-4600-b755-61e1fa90cd5d","added_by":"auto","created_at":"2025-07-16 17:46:42","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":9463846,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6432057/v1/717c2b61-edea-4cc8-abcc-139a9af44215.pdf"},{"id":82003305,"identity":"ad1cedb1-ea3c-43fd-a744-d620588728d7","added_by":"auto","created_at":"2025-05-05 20:37:44","extension":"zip","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":3053740,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryMaterial2.zip","url":"https://assets-eu.researchsquare.com/files/rs-6432057/v1/6c1c3012d71f31d15bc5ad60.zip"}],"financialInterests":"No competing interests reported.","formattedTitle":"Comparative Outcomes of Split versus Whole Liver Transplantation in Adult ESLD Recipients: A Multicenter Propensity-Matched Analysis","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eLiver transplantation (LT) is an effective treatment for end-stage liver disease, certain metabolic disorders, and liver tumors\u003csup\u003e(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e)\u003c/sup\u003e,with 2024 EASL guidelines reaffirming its therapeutic primacy in both curative and palliative contexts\u003csup\u003e(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e)\u0026zwnj;\u003c/sup\u003e,yet donor liver shortages persist globally. China's organ supply-demand ratio reached 1:6 in 2021\u003csup\u003e(\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e)\u003c/sup\u003e, necessitating innovative solutions like split liver transplantation (SLT) - a technique enabling dual/multiple recipients per donor liver through anatomical segmentation \u003csup\u003e(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e)\u003c/sup\u003e. This technique theoretically doubles the donor pool, alleviating the shortage of donor livers and reducing the waiting time for recipients \u003csup\u003e(\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e)\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eCurrently, SLT is still evolving worldwide. According to the 2021 annual report of the United States Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR), 16.6% of pediatric liver transplants were SLT\u003csup\u003e(\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e)\u003c/sup\u003e, and the procedure is also widely practiced in Europe for pediatric cases\u003csup\u003e(\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e)\u003c/sup\u003e. Although SLT is well-established in pediatric transplantation, its use in adults remains limited \u003csup\u003e(\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e)\u003c/sup\u003e. SLT's technical complexity correlates with elevated risks of biliary/vascular complications \u003csup\u003e(\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e)\u003c/sup\u003e.In adults, split liver grafts are often considered riskier than whole liver grafts due to the potential for biliary and vascular complications resulting from the liver parenchyma transection, which can significantly impact graft and recipient survival\u003csup\u003e(\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e) (\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e)\u003c/sup\u003e. While some studies equate SLT and whole liver transplantation (WLT) safety \u003csup\u003e(\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e)\u003c/sup\u003e. Globally, the prognosis of SLT versus WLT in adults with hepatocellular carcinoma (HCC) and non-HCC end-stage liver disease (ESLD) is not well-documented,and evidence gaps persist regarding adult HCC vs. non-HCC ESLD outcomes (current literature) and donor-type impacts under China's unique C-I (DBD)/C-II (DCD)/C-III (DBCD) classification system\u003csup\u003e(\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e)\u003c/sup\u003e. Therefore, based on China Liver Transplant Registry(CLTR), we employed propensity score matching (PSM) - an advanced statistical approach that effectively balances confounding variables in observational research by creating comparable cohorts, thereby approximating randomized controlled trial conditions \u003csup\u003e(\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e)\u003c/sup\u003e.Through comprehensive univariate and multivariate Cox regression analyses, we identified and compared critical prognostic factors influencing overall survival (OS) in HCC versus non-HCC recipients. Furthermore, we conducted a novel lateralized analysis to investigate potential graft orientation-related outcomes by comparing postoperative prognoses between recipients of lefthemiliver versus right hemiliver and right trisegment grafts in SLT procedures.Finally, the study investigated the incidence of postoperative complications that occur following liver transplantation.\u003c/p\u003e"},{"header":"Patients and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy population\u003c/h2\u003e \u003cp\u003eThe details liver transplants performed from January 2018 to December 2022 from 13 transplant centers in China, were collected by the CLTR. This was performed according to the Declaration of Helsinki (as revised in 2013) and approved by the CLTR (No. 20230030). Informed consent was obtained from all the patients for the use of their data for research purposes. Voluntarily donated organs from citizens have become the sole legitimate source of transplantable organs from deceased donors in China science January 2015 \u003csup\u003e(\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e)\u003c/sup\u003e. It is important to note that all deceased organ donations in China are nondirected donations. Additionally, to ensure fair, just, open, and traceable allocation, all organs from deceased donors are automatically allocated through the China Organ Transplant Response System in accordance with national policies \u003csup\u003e(\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e)\u003c/sup\u003e. None of the patients in this study received liver grafts from prisoners. All HCC transplant patients met the Hangzhou criteria\u003csup\u003e(\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e)\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eAfter excluding pediatric LT, re-transplantation, multi-organ transplantation, living donor transplantation, and incomplete data, 5419 adult WLT and 559 adult SLT patients were enrolled in this study. Among these, 2308 patients with HCC and 3111 patients with non-HCC ESLD received WLT, while 214 HCC and 345 non-HCC ESLD patients underwent SLT.\u003c/p\u003e \u003cp\u003eFor the purpose of this study, SLT recipients were matched with WLT recipients using PSM at a 1:1 ratio. Matching criteria included age, sex, year of operation, MELD score, donor type, donor and recipient BMI, primary disease, CIT, WIT, operation time, and other relevant factors. After PSM, the characteristics of 536 SLT recipients were compared with those of 536 WLT recipients \u003cem\u003e(\u003c/em\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e\u003cem\u003e)\u003c/em\u003e. The study has been reported in line with the STROCSS criteria\u003csup\u003e(\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e)\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eTechnical Specifications\u003c/h3\u003e\n\u003cp\u003eChina's split liver transplantation (SLT) protocols systematically integrate anatomical optimization and ischemia mitigation strategies. Donor selection follows stringent biological criteria:(1)Normal hepatic function (ALT\u0026thinsp;\u0026lt;\u0026thinsp;40 U/L, AST\u0026thinsp;\u0026lt;\u0026thinsp;35 U/L);(2)Absence of steatosis (\u0026gt;\u0026thinsp;30% macrosteatosis exclusion)(3)Anatomical integrity confirmed by triphasic CT/MR cholangiography.In adult SLT, two primary liver splitting techniques are commonly used:\u003c/p\u003e \u003cp\u003e(1)Full Left-Right Graft Partitioning:The parenchymal transection plane follows the principal portal fissure (Cantlie line), preserving:① Right graft: Hepatic artery segment IV branch, right portal vein (\u0026ge;\u0026thinsp;8 mm diameter), and sectoral bile ducts (Couinaud segments V-VIII),②Left graft: Left hepatic vein trunk (\u0026ge;\u0026thinsp;5 mm) and segment II/III biliary confluence Right grafts target recipients with BMI\u0026thinsp;\u0026gt;\u0026thinsp;25, while left grafts serve BMI\u0026thinsp;\u0026lt;\u0026thinsp;22 adults.(2)Right Trisection Graft Preparation:The division plane extends along the right hepatic vein, creating:① Trisection graft: Segments IV-VIII with intact middle hepatic vein reconstructed via interposition grafts②Left lateral graft: Segments II-III with preserved umbilical fissure vasculature.This technique achieves 1.2% hepatic artery thrombosis rate through microsurgical anastomosis (8\u0026thinsp;\u0026minus;\u0026thinsp;0 polypropylene) under 3.5\u0026times; loupe magnification.\u003c/p\u003e \u003cp\u003eBoth approaches mandate sequential vascular clamping (total ischemia\u0026thinsp;\u0026lt;\u0026thinsp;45 min) and real-time indocyanine green perfusion testing to validate biliary-vascular patency. Graft selection prioritizes portal flow symmetry (Doppler-verified flow velocity differential\u0026thinsp;\u0026lt;\u0026thinsp;15 cm/s) and recipient anthropometrics (graft-to-recipient weight ratio\u0026thinsp;\u0026ge;\u0026thinsp;0.8%).\u003c/p\u003e\n\u003ch3\u003eData collection\u003c/h3\u003e\n\u003cp\u003eWe collected clinical information prior to LT, including age, sex, operation year, MELD score, type of donor, donor and recipient BMI, primary disease, and other relevant factors. Additionally, intraoperative data such as CIT, WIT, and operation time were also gathered. Postoperative complications within 90 days of hospitalization were documented, including intra-abdominal bleeding, new-onset hypertension, newly diagnosed diabetes, graft-versus-host disease (GVHD), bile duct complications, vascular complications, early allograft dysfunction(EAD), pleural effusion, pulmonary edema, acute kidney injury(AKI), and postoperative infection. It should be noted that patients who received a right half liver graft were transplanted with segments S5-8, while those who received a right tri-segment graft were transplanted with segments S4-8. The selection of the donor liver was based on a comprehensive evaluation that included the donor liver size and GRWR, the recipient's liver function status, donor vascular anatomy, surgical complexity, and the associated risk of complications.\u003c/p\u003e \u003cp\u003eVascular complications included anastomotic stenosis, torsion, and thrombosis, while bile duct complications encompassed anastomotic stenosis, torsion, and bile leakage. The primary endpoints of this analysis were patient death or tumor recurrence. All complications were thoroughly documented during the patient's hospitalization.\u003c/p\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003eThe statistical analysis was performed using the statistical software SAS, version 9.4 software (SAS Institute Inc). Quantitative variables are expressed as the mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation or median and range depending on the distribution. Categorical variables are presented as values and percentages. Student t-test or nonparametric test were used to compare quantitative variables with or without a bell-shaped distribution. Chi-square test was used to compare categorical variables. OS and DFS were calculated using the Kaplan\u0026ndash;Meier method. For survival analysis, a log-rank test was used to assess group difference. To identify risk factors for OS, a multivariate analysis was performed. The Odds Ratio (OR) and its 95% confidence interval (CI) were estimated in the univariable and multivariable logistic regression analyses. All tests were two-sided, with a P value of \u0026lt;\u0026thinsp;0.05 considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eBaseline characteristics and outcomes\u003c/h2\u003e \u003cp\u003eAfter propensity score matching (PSM), 536 liver transplant recipients were included in the comparative analysis. Pre-PSM analysis revealed significant intergroup disparities in sex distribution (female: 65.7% vs 80.8%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001), biological parameters (MELD score: 24.4 vs 26.9; BMI: 22.0 vs 23.4 kg/m\u0026sup2;), and operative characteristics (WIT: 3.3 vs 5.1 min; GRWR: 1.5 vs 2.1; all P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). Post-PSM cohort balancing eliminated baseline differences in demographic parameters, donor types, and ischemia times (all P\u0026thinsp;\u0026gt;\u0026thinsp;0.05), with the exception of persistently lower GRWR in SLT recipients 1.5 vs2.4, P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001).\u003c/p\u003e \u003cp\u003eDuring the median follow-up of 18.5 months (mean 22.4 months), SLT demonstrated comparable safety profiles to WLT regarding metabolic complications (new-onset diabetes: 9.9% vs 12.9%; hypertension: 1.7% vs 2.8%) and organ-specific sequelae (pleural effusion: 17% vs 16%; pulmonary edema: 0.4% vs 0%; all P\u0026thinsp;\u0026gt;\u0026thinsp;0.05). However, SLT was associated with elevated risks of immediate postoperative morbidity:(1)Intra acute bleeding (6.7% vs 3.2%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05)(2)Biliary complications (3.9% vs 1.9%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05)(3)Vascular complications (3.9% vs 1.1%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05).Notably, critical endpoints including early allograft dysfunction (EAD: 13.1% vs 11.4%), graft-versus-host disease (GVHD: 2.3% vs 1.7%), and systemic infections (18.9% vs 16.3%) showed no statistical intergroup divergence (all P\u0026thinsp;\u0026gt;\u0026thinsp;0.05)\u003cem\u003e(Table \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e)\u003c/em\u003e.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003e‌Matched cohort analysis in HCC patients of WLT and SLT\u003c/h3\u003e\n\u003cp\u003eFollowing 1:1 PSM of 202 SLT and 202 WLT recipients with hepatocellular carcinoma, baseline comparability was achieved for oncological parameters (tumor number, maximum diameter), demographic characteristics (age, sex, MELD score), and perioperative metrics (CIT, WIT, ABO mismatch ratio; all P\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Two critical disparities persisted in the SLT cohort:(1)Significantly reduced hemoglobin levels (69.2 vs 104.9 g/L, P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001)(2)Lower median graft-to-recipient weight ratio (1.4% vs 2.1%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001).Postoperative analysis revealed SLT-specific morbidity patterns:(1)increased risk of early allograft dysfunction (EAD: 25.7% vs 16.8%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 );(2)higher incidence of pleural effusion (17.3% vs 9.9%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001)\u003c/p\u003e \u003cp\u003eNotably, other surgical complications including biliary complications (3.5% vs 2.0%), vascular thrombosis (3.0% vs 1.0%), and systemic infections (13.4% vs 11.4%) demonstrated comparable rates between cohorts (all P\u0026thinsp;\u0026gt;\u0026thinsp;0.05)\u003cem\u003e(\u003c/em\u003eTable\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e\u003cem\u003e).\u003c/em\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eHCC recipient characteristics of enrolled cohort\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHCC recipients\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c4\" namest=\"c2\"\u003e \u003cp\u003eBefore PSM\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003eAfter PSM\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSLT(n\u0026thinsp;=\u0026thinsp;214)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eWLT(n\u0026thinsp;=\u0026thinsp;2308)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eSLT(n\u0026thinsp;=\u0026thinsp;202)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eWLT(n\u0026thinsp;=\u0026thinsp;202)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003ePreoperative baseline characteristics\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale, n\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e168\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2073\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e163\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e158\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5381\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge, mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e53.1(\u0026plusmn;\u0026thinsp;9.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53.6(\u0026plusmn;\u0026thinsp;9.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.4930\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e53.1(\u0026plusmn;\u0026thinsp;9.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e52.7(\u0026plusmn;\u0026thinsp;9.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.6363\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOperation year\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.8295\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2018\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e309\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2019\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e323\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2020\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e447\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2021\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e607\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2.2022.1-2022.12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e622\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMELD score, mean(\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e21.0(\u0026plusmn;\u0026thinsp;12.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22.9(\u0026plusmn;\u0026thinsp;12.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0396\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e21.2(\u0026plusmn;\u0026thinsp;12.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e21.0(\u0026plusmn;\u0026thinsp;12.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.9166\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTumor classification\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c8\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFulfilling Milan criteria,n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e88(41.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e971(42.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.5750\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e82(40.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e91(45.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5058\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExceeding Milan but fulfilling Hang zhou(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e40(18.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e368(15.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.5660\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e40(19.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e32(15.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5870\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExceeding Hangzhou(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e86(40.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e969(42.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.5768\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e80(39.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e79(39.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5532\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNumber of tumors, n\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.2002\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5860\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e103\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1203\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e124\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e117\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u0026ndash;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e454\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026gt;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e651\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAFP, n\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1493\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0989\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e132\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1471\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e97\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e113\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e100\u0026ndash;400\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e276\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;400\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e561\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eThe biggest tumor diameter(cm),n\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.5495\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.1360\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e98\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e954\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e102\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u0026ndash;5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e543\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u0026ndash;7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e283\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e528\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlbumin,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e34.5(\u0026plusmn;\u0026thinsp;6.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34.5(\u0026plusmn;\u0026thinsp;7.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.9965\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e34.3(\u0026plusmn;\u0026thinsp;6.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e35.0(\u0026plusmn;\u0026thinsp;6.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.2984\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eALT,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e137.2(\u0026plusmn;\u0026thinsp;578.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e113.0(\u0026plusmn;\u0026thinsp;427.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.6001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e145.4(\u0026plusmn;\u0026thinsp;599.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e85.8(\u0026plusmn;\u0026thinsp;235.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.2523\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAST,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e194.4(\u0026plusmn;\u0026thinsp;624.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e188.9(\u0026plusmn;\u0026thinsp;689.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.9210\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e206.3(\u0026plusmn;\u0026thinsp;646.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e181.3(\u0026plusmn;\u0026thinsp;707.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.7510\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTotal Bilirubin,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e157.9(\u0026plusmn;\u0026thinsp;185.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e195.3(\u0026plusmn;\u0026thinsp;1168.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1718\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e158.0(\u0026plusmn;\u0026thinsp;186.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e142.7(\u0026plusmn;\u0026thinsp;167.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3851\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemoglobin,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e70.1(\u0026plusmn;\u0026thinsp;52.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e100(\u0026plusmn;\u0026thinsp;53.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e69.2(\u0026plusmn;\u0026thinsp;52.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e104.9(\u0026plusmn;\u0026thinsp;38.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eType of Donor\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0535\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDBD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e124\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e825\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e117\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e106\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDCD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e952\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDBCD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e531\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo; BMI,median(IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e22.8(20.6\u0026ndash;24.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23.6(21.6\u0026ndash;25.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e22.9(20.7\u0026ndash;24.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e22.6(20.8\u0026ndash;24.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.6075\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonors\u0026rsquo; BMI, median (IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23.4(21.8\u0026ndash;25.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23.4(21.5\u0026ndash;25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.4150\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e23.4(21.7\u0026ndash;24.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e23.2(21.2\u0026ndash;25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.9594\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePer operative data\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCIT(h), mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.5(\u0026plusmn;\u0026thinsp;2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.0(\u0026plusmn;\u0026thinsp;2.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0240\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5.5(\u0026plusmn;\u0026thinsp;2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e5.7(\u0026plusmn;\u0026thinsp;2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.9478\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWIT (min), mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e40(\u0026plusmn;\u0026thinsp;7.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e52(\u0026plusmn;\u0026thinsp;7.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0142\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e41(\u0026plusmn;\u0026thinsp;7.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e38(\u0026plusmn;\u0026thinsp;6.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.6661\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOperation time(h), mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7.3(\u0026plusmn;\u0026thinsp;2.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.6(\u0026plusmn;\u0026thinsp;1.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.2(\u0026plusmn;\u0026thinsp;2.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7.1(\u0026plusmn;\u0026thinsp;1.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5087\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eABO-incompatible, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5(3.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e69(3.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.5881\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5(2.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2(1.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.2527\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGRWR(%), median(IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.4(1.2\u0026ndash;1.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.1(1.8\u0026ndash;2.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.4(1.2\u0026ndash;1.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.1(1.8\u0026ndash;2.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClassification of split donor liver, n\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLeft half liver\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRight half or right tri-segment liver\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e175\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e171\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePostoperative complications\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIntra-Abdominal Bleeding, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10(4.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e85(3.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.4580\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e9(4.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e5(2.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.2724\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBiliary Complications, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8(3.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e49(2.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1251\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7(3.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4(2.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3547\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVascular Complication, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6(2.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20(0.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0070\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6(3.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2(1.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.1511\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEAD, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55(25.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e427(18.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0104\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e52(25.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e34(16.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0287\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNew-onset Diabetes Mellitus, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e19(8.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e313(13.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0550\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e18(9.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e21(10.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.6247\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNew-onset Hypertension, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4(1.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e84(3.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1802\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3(1.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e6(3.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3155\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePleural Effusion, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e38(17.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e347(15.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.2761\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e35(17.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e20(9.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0281\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePulmonary Edema, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1(0.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0009\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1(0.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3143\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGVHD, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAKI,n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e54(25.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e492(21.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1833\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e50(24.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e63(31.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.1496\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfection\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePulmonary infection, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e28(13.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e347(15.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.4570\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e27(13.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e23(11.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5455\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCatheter Sepsis, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1(0.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4(0.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.3530\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1(0.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3155\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUrinary Tract Infection, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4(0.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.5431\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWound Infection, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4(1.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13(0.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0251\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4(2.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1(0.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.1752\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003eCIT, cold ischemia time; WIT, warm ischemia time; BMI, body mass index; LT, liver transplant; MELD, Model for End-stage Liver Disease;\u0026nbsp;GRWR,graft-to-recipient weight ratio; HCC, hepatocellular carcinoma;EAD, early allograft dysfunction; PTLD, posttransplant lymphoproliferative disorders; GVHD, graft-versus-host disease; AKI, acute kidney injury.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e\n\u003ch3\u003e‌Matched cohort analysis in Non-HCC ESLD patients of WLT and SLT\u003c/h3\u003e\n\u003cp\u003eThrough 1:1 propensity score matching of 318 SLT and 318 WLT recipients with non-HCC ESLD, balanced baseline characteristics were achieved for disease etiology (primary diagnosis distribution), transplant parameters (CIT: 5.8 vs 5.5 hr; WIT: 31 vs 32 min), and operative profiles (operation time: 7.3 vs 7.2 hr; all P\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Two clinically relevant intergroup disparities persisted:(1)Lower pre-transplant hemoglobin in SLT cohort (53.9 vs 74.9g/L,P\u0026thinsp;\u0026lt;\u0026thinsp;0.0001)(2)Reduced graft adequacy(GRWR: 1.5% vs 2.5%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001).Postoperative analysis demonstrated distinct complication profiles compared to WLT group:(1)increased risk of intra-abdominal bleeding (13.5% vs 8.5%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05);(2)higher vascular complications (4.7% vs 1.9%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05).\u003c/p\u003e \u003cp\u003eNotably, this complication pattern diverged from HCC patients who exhibited higher EAD risk. Critical endpoints including biliary complications (14% vs 6.0%), pleural effusion (17.3% vs 16.4%) remained comparable between cohorts (all P\u0026thinsp;\u0026gt;\u0026thinsp;0.05)\u003cem\u003e(\u003c/em\u003eTable\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e\u003cem\u003e)\u003c/em\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eNon-HCC recipient characteristics of enrolled cohort\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eNon-HCC recipients\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c4\" namest=\"c2\"\u003e \u003cp\u003eBefore PSM\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e \u003cp\u003eAfter PSM\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSLT(n\u0026thinsp;=\u0026thinsp;345)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eWLT(n\u0026thinsp;=\u0026thinsp;3111)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eSLT(n\u0026thinsp;=\u0026thinsp;318)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eWLT(n\u0026thinsp;=\u0026thinsp;318)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003ePreoperative baseline characteristics\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePrimary diagnosis\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDecompensation of cirrhosis,n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e232(67.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1583(50.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e210(66.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e202(63.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5066\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLiver failure,n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e84(24.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e926(29.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0358\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e81(25.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e78(24.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.7835\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMetabolic disease,n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9(2.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25(0.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0013\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e4(1.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e9(2.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.1612\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers,n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13(3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50(1.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0044\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e11(3.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7(2.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3388\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eFemale, n\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e199\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2304\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e127\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e136\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.4687\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAge, mean (\u0026plusmn;\u0026thinsp;SD)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e51.6(\u0026plusmn;\u0026thinsp;11.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e49.6(\u0026plusmn;\u0026thinsp;10.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0028\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e51.3(\u0026plusmn;\u0026thinsp;11.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e50.8(\u0026plusmn;\u0026thinsp;10.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5394\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOperation year\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0108\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2018\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e765\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2019\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e717\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2020\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e513\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2021\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e112\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e509\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e97\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2022.1-2022.12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e105\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e607\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e97\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e116\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMELD score, mean(\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26.6(\u0026plusmn;\u0026thinsp;11.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29.9(\u0026plusmn;\u0026thinsp;10.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e27.2(\u0026plusmn;\u0026thinsp;11.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e27.4(\u0026plusmn;\u0026thinsp;10.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.8235\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlbumin,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e32.9(\u0026plusmn;\u0026thinsp;6.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32.9(\u0026plusmn;\u0026thinsp;9.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.9738\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e33.0(\u0026plusmn;\u0026thinsp;6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e33.6(\u0026plusmn;\u0026thinsp;14.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.4914\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eALT,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e93.9(\u0026plusmn;\u0026thinsp;329.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e129.8(\u0026plusmn;\u0026thinsp;425.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1346\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100.2(\u0026plusmn;\u0026thinsp;346.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e124.4(\u0026plusmn;\u0026thinsp;393.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5143\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAST,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e117.7(\u0026plusmn;\u0026thinsp;302.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e176.5(\u0026plusmn;\u0026thinsp;705.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0279\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e125.5(\u0026plusmn;\u0026thinsp;318.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e151.8(\u0026plusmn;\u0026thinsp;477.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.5259\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTotal Bilirubin,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e240.8(\u0026plusmn;\u0026thinsp;206.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e287.3(\u0026plusmn;\u0026thinsp;201.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e251.1(\u0026plusmn;\u0026thinsp;208.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e252.2(\u0026plusmn;\u0026thinsp;197.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.9449\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemoglobin,mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55.7(\u0026plusmn;\u0026thinsp;42.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e75.0(\u0026plusmn;\u0026thinsp;46.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e53.9(\u0026plusmn;\u0026thinsp;42.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e74.9(\u0026plusmn;\u0026thinsp;38.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eType of Donor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3745\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDBD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e211\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1244\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e192\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e188\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDCD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1194\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDBCD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e673\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e49\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo; BMI, median(IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e21.5(19.1\u0026ndash;23.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23.1(21.0-25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e21.6(19.4\u0026ndash;23.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e21.5(19.5\u0026ndash;23.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.7713\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonors\u0026rsquo; BMI, median(IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23.6(21.6\u0026ndash;25.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23.4(21.4\u0026ndash;25.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0472\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e23.6(21.6\u0026ndash;25.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e23.4(21.2\u0026ndash;26.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.7536\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePer operative data\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCIT(h), mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.8(\u0026plusmn;\u0026thinsp;2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.0(\u0026plusmn;\u0026thinsp;3.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1187\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e5.8(\u0026plusmn;\u0026thinsp;2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e5.5(\u0026plusmn;\u0026thinsp;3.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.2043\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWIT(min), mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e29(\u0026plusmn;\u0026thinsp;5.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e51(\u0026plusmn;\u0026thinsp;7.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e31(\u0026plusmn;\u0026thinsp;5.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e32(\u0026plusmn;\u0026thinsp;5.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.8305\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOperation time(h), mean (\u0026plusmn;\u0026thinsp;SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7.5(\u0026plusmn;\u0026thinsp;2.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6.6(\u0026plusmn;\u0026thinsp;1.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.3(\u0026plusmn;\u0026thinsp;2.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7.2(\u0026plusmn;\u0026thinsp;2.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.6054\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eABO-incompatible, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9(2.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e178(5.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0153\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e9(2.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e9(2.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGRWR(%), median(IQR)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.6(1.2\u0026ndash;1.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.1(1.8\u0026ndash;2.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.5(1.2\u0026ndash;1.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.5(2.1-3.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eClassification of split donor liver,n\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLeft half liver\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRight half or right tri-segment liver\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e272\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e252\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePostoperative complications\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIntra-Abdominal Bleeding, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27(7.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e153(4.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0214\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e27(8.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11(3.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0074\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBiliary Complications, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15(4.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e71(2.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0197\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e14(4.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e6(1.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0691\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVascular Complication, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16(4.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37(1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.0001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e15(4.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e6(1.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0458\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEAD, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e95(27.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e676(21.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0140\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e89(28.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e68(21.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0535\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNew-onset Diabetes Mellitus, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e39(11.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e441(14.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.1400\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e35(11.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e44(13.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.2792\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNew-onset Hypertension, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8(2.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e84(2.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.6725\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7(2.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4(1.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3643\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePleural Effusion, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e59(17.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e519(16.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.8533\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e55(17.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e52(16.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.7505\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePulmonary Edema, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.9095\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGVHD, n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2(0.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.2510\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.2830\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAKI,n(%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e106(30.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e787(25.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.0289\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100(31.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e81(25.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0950\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfection\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePulmonary infection, n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e65(18.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e578(18.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.9166\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e59(18.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e58(18.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.9185\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCatheter Sepsis, n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3(0.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.3169\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUrinary Tract Infection, n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3(0.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.3169\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1(0.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.3169\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWound Infection, n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2(0.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33(1.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.3980\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2(0.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4(1.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.4142\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"8\" nameend=\"c8\" namest=\"c1\"\u003e \u003cp\u003eCIT, cold ischemia time; WIT, warm ischemia time; BMI, body mass index; LT, liver transplant; MELD, Model for End-stage Liver Disease; GRWR,graft-to-recipient weight ratio; HCC, hepatocellular carcinoma;EAD, early allograft dysfunction; PTLD, posttransplant lymphoproliferative disorders; GVHD, graft-versus-host disease; AKI, acute kidney injury\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eOverall Survival\u003c/h2\u003e \u003cp\u003eComparative survival analysis revealed differential outcomes before and after PSM. In the pre-matched cohort, WLT recipients demonstrated nominally superior OS rates compared to SLT counterparts, with 1-, 3-, and 5-year OS of 85.3% vs 79.1%, 75.0% vs 71.0%, and 68.7% vs 66.2% respectively (log-rank P\u0026thinsp;=\u0026thinsp;0.003). However, this survival disparity was attenuated following 1:1 PSM, where comparable OS outcomes emerged between matched cohorts (WLT: 83.0%, 74.4%, 61.8% vs SLT: 78.8%, 70.5%, 65.8%; log-rank P\u0026thinsp;=\u0026thinsp;0.159) (eFigure1).\u003c/p\u003e \u003cp\u003eThe study cohort was stratified into HCC and non-HCC ESLD subgroups. In the HCC cohort prior to propensity score matching (PSM), comparable overall survival (OS) was observed between split liver transplantation (SLT) and whole liver transplantation (WLT) recipients (P\u0026thinsp;=\u0026thinsp;0.350, eFigure2A). Following 1:1 PSM (n\u0026thinsp;=\u0026thinsp;202 per group), Kaplan-Meier analysis demonstrated no statistically significant differences in post-transplant outcomes between matched cohorts. The SLT group exhibited 1-, 3-, and 5-year OS rates of 78.8%, 70.5%, and 65.8% respectively, compared with 83.0%, 74.4%, and 61.8% in the WLT group (log-rank P\u0026thinsp;=\u0026thinsp;0.088). Disease-free survival (DFS) rates were similarly comparable between groups (74.3%, 64.7%, 61.9% vs 81.0%, 70.8%, 60.7%; log-rank P\u0026thinsp;=\u0026thinsp;0.111) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA-B).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eSubgroup analysis of HCC recipients based on tumor burden criteria revealed comparable survival outcomes across three distinct categories: those fulfilling Milan criteria, those exceeding Milan but fulfilling Hangzhou criteria, and those surpassing Hangzhou criteria (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC-E). Surgical approach analysis demonstrated equivalent prognostic outcomes between SLT recipients receiving left hemiliver grafts versus right trisegment grafts. Notably, post-PSM analysis revealed no significant disparity in tumor recurrence patterns between SLT and WLT cohorts, with 1- and 3-year recurrence rates of 10.3% vs 15.1% (P\u0026thinsp;=\u0026thinsp;0.604) and 16.3% vs 15.4% respectively (eFigure 2B).\u003c/p\u003e \u003cp\u003eFor non-HCC patients,pre-PSM Analysis\u0026zwnj;: Whole liver transplantation (WLT; n\u0026thinsp;=\u0026thinsp;3,111) demonstrated significantly higher overall survival (OS) rates compared to split liver transplantation (SLT; n\u0026thinsp;=\u0026thinsp;345) before propensity score matching (PSM). Kaplan-Meier estimates revealed 1-, 3-, and 5-year OS rates of 84.3%, 80.0%, and 76.3% for WLT versus 79.1%, 74.2%, and 65.9% for SLT, respectively (log-rank P\u0026thinsp;=\u0026thinsp;0.015; Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA);Post-PSM Comparison\u0026zwnj;: After 1:1 PSM (WLT: n\u0026thinsp;=\u0026thinsp;318; SLT: n\u0026thinsp;=\u0026thinsp;318), the survival advantage of WLT was attenuated, with no statistically significant difference observed between matched groups (1-/3-/5-year OS: 84.0%/79.2%/76.1% vs. 78.2%/72.8%/64.0%; P\u0026thinsp;=\u0026thinsp;0.074; Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB); SLT Graft-Type Subanalysis\u0026zwnj;: Among post-PSM SLT recipients, those receiving right hemi-liver or right tri-segment grafts (n\u0026thinsp;=\u0026thinsp;255) exhibited markedly superior prognosis compared to left hemi-liver graft recipients (n\u0026thinsp;=\u0026thinsp;66). The 1- and 3-year OS rates were 82.2% vs. 63.4% and 77.2% vs. 57.8%, respectively (log-rank P\u0026thinsp;\u0026lt;\u0026thinsp;0.001; Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eRisk factors for Overall Survival\u003c/h2\u003e \u003cp\u003eTo delineate prognostic determinants of post-transplant survival, we performed comprehensive risk stratification through sequential univariable and multivariable analyses in HCC and non-HCC cohorts. Variables achieving statistical significance (P\u0026thinsp;\u0026lt;\u0026thinsp;0.05) in univariable screening were subjected to multivariable Cox proportional hazards regression.\u003c/p\u003e \u003cp\u003eFor \u0026zwnj;HCC recipients\u0026zwnj;,multivariable modeling identified six independent predictors of reduced OS):(1)Elevated donor body mass index (BMI: HR\u0026thinsp;=\u0026thinsp;1.039 per kg/m\u0026sup2;, 95% CI 1.016\u0026ndash;1.063, P\u0026thinsp;=\u0026thinsp;0.001);(2)Recipient BMI (HR\u0026thinsp;=\u0026thinsp;0.965 per kg/m\u0026sup2;, 95% CI 0.942\u0026ndash;0.990, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001);(3)MELD score\u0026thinsp;\u0026gt;\u0026thinsp;25 (HR\u0026thinsp;=\u0026thinsp;1.574, 95% CI 1.336\u0026ndash;1.854, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001);\u003c/p\u003e \u003cp\u003e(4)Prolonged cold ischemia time (CIT: HR\u0026thinsp;=\u0026thinsp;1.101 per hour, 95% CI 1.072\u0026ndash;1.131, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001);\u003c/p\u003e \u003cp\u003e(5)Tumors exceeding Milan criteria while meeting Hangzhou criteria (HR\u0026thinsp;=\u0026thinsp;1.718, 95% CI 1.308\u0026ndash;2.257, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001);(6)Tumors surpassing Hangzhou criteria (HR\u0026thinsp;=\u0026thinsp;3.291, 95% CI 2.701\u0026ndash;4.011, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001).\u003c/p\u003e \u003cp\u003eFor \u0026zwnj;Non-HCC recipients,\u0026zwnj;three factors independently predicted inferior OS:(1)Advanced recipient age (HR\u0026thinsp;=\u0026thinsp;1.026 per year, 95% CI 1.017\u0026ndash;1.034, P\u0026thinsp;=\u0026thinsp;0.001);(2)Extended CIT duration (HR\u0026thinsp;=\u0026thinsp;1.070 per hour, 95% CI 1.042-1.100, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001);(3)SLT(vs. WLT: HR\u0026thinsp;=\u0026thinsp;1.555, 95% CI 1.209-2.000, P\u0026thinsp;=\u0026thinsp;0.001).Notably, comprehensive evaluation of donor characteristics (vascular anatomy, graft quality) and recipient anatomical factors demonstrated no significant associations with OS in either cohort through univariable analysis \u003cem\u003e(\u003c/em\u003eTable\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e\u003cem\u003e)\u003c/em\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eUnivariable and Multivariable analysis of risk factors for OS\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"12\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre-translplant risk factor for OS\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"5\" nameend=\"c6\" namest=\"c2\"\u003e \u003cp\u003eUnivariable\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"6\" nameend=\"c12\" namest=\"c7\"\u003e \u003cp\u003eMultivariable\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eIC95%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003eP-value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003eHR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003eIC95%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c12\" namest=\"c11\"\u003e \u003cp\u003eP-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHCC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"11\" nameend=\"c12\" namest=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonors\u0026rsquo; age\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.005\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.999\u0026ndash;1.011\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.096\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonors\u0026rsquo; BMI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.036\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.012\u0026ndash;1.060\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.003\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.039\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e1.016\u0026ndash;1.063\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo; age\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.005\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.996\u0026ndash;1.014\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.261\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo; BMI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e0.961\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.938\u0026ndash;0.985\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.002\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0.965\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e0.942\u0026ndash;0.990\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo;MELD\u0026gt;25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.714\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.457\u0026ndash;2.016\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.574\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e1.336\u0026ndash;1.854\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCIT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.104\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.076\u0026ndash;1.133\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.101\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e1.072\u0026ndash;1.131\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWLT / SLT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.193\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.887\u0026ndash;1.603\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.350\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFulfilling Milan(baseline)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"11\" nameend=\"c12\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExceeding Milan but fulfilling Hang zhou\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.764\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.343\u0026ndash;2.317\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.718\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e1.308\u0026ndash;2.257\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExceeding Hangzhou\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e3.359\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e2.757\u0026ndash;4.092\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e3.291\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e2.701\u0026ndash;4.011\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNon-HCC\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"11\" nameend=\"c12\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonors\u0026rsquo; age\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.002\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.999\u0026ndash;1.005\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.300\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonors\u0026rsquo; BMI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e0.985\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.961\u0026ndash;1.010\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.228\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo; age\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.016\u0026ndash;1.033\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.026\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e1.017\u0026ndash;1.034\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo; BMI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e0.981\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.957\u0026ndash;1.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.109\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecipients\u0026rsquo; MELD\u0026gt;25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.080\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.903\u0026ndash;1.292\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.400\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCIT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.084\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.055\u0026ndash;1.113\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.070\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e1.042-1.100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSLT/WLT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e1.438\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.120\u0026ndash;1.847\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.015\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.555\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e1.209-2.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"12\"\u003eCIT, cold ischemia time; BMI, body mass index; MELD, Model for End-stage Liver Disease.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eHerein, we present the world's largest multicenter sample analyzing the outcomes of adult liver transplantation patients, with a focus on the application of SLT in this population. Our findings underscore the non-inferiority of SLT versus WLT in terms of OS among adult recipients (P\u0026thinsp;\u0026gt;\u0026thinsp;0.05), highlighting its potential as a viable strategy to address the persistent organ shortage.Despite the uncertainty surrounding the progression of hepatocellular carcinoma (HCC), up to 30% of HCC patients awaiting transplantation may develop contraindications due to tumor progression\u003csup\u003e(\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e)\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe topic of partial liver transplantation for HCC has long been a subject of significant scholarly interest and discussion. A study conducted by 81 transplant centers in China concluded that there was no statistically significant difference in OS and DFS between LDLT and WLT in HCC patients. \u003csup\u003e(\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e)\u003c/sup\u003e Similarly, a study from the United States found no statistical difference in graft survival curves between SLT and WLT in HCC patients \u003csup\u003e(\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e)\u003c/sup\u003e. Our study, in line with previous research, found no statistically significant difference in OS and DFS between SLT and WLT in HCC patients (P\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Further validating our results, we observed comparable tumor recurrence rates between the two groups (1-year and 3-year recurrence rates: 10.3% and 16.3% vs 11.6% and 29.0%, respectively; P\u0026thinsp;=\u0026thinsp;0.576). These findings suggest that SLT is a safe and effective option for adult HCC patients, particularly under rigorous oncological surveillance and stringent selection criteria.In non-HCC ESLD patients, while we did not observe a statistically significant difference in OS between SLT and WLT PSM, a notable difference emerged in the type of graft received. Specifically, recipients of right hemiliver or right trisegment grafts demonstrated superior long-term survival compared to those receiving left hemiliver grafts (1-year OS: 82.2% vs. 63.4%; 3-year OS: 77.2% vs. 57.8%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001). This finding highlights the importance of graft-type optimization in maximizing the outcomes of SLT in non-HCC ESLD patients.\u003c/p\u003e \u003cp\u003eThe implementation of SLT in non-HCC ESLD patients presents persistent challenges requiring multidisciplinary coordination among transplant teams, meticulous evaluation of donor-recipient compatibility, and precise execution of technically demanding procedures including vascular/biliary segmentation and graft reconstruction \u003csup\u003e(\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e)\u003c/sup\u003e. Our propensity-matched analysis revealed distinct complication profiles, with SLT recipients exhibiting significantly higher rates of intra-abdominal bleeding (13.5% vs 8.5%,P\u0026thinsp;\u0026lt;\u0026thinsp;0.05) and vascular complications (4.7% vs 1.9%,P\u0026thinsp;\u0026lt;\u0026thinsp;0.05 )in adult non-HCC ESLD patients. These disparities may stem from the compounded effects of:(1)Impaired hepatic functional reserve in ESLD patients limiting regenerative capacity;(2)Immunosuppression-mediated interference with post-operative healing;(3)Anatomical complexity inherent to partial-graft vascular anastomoses.Notably, the vascular complication rate aligns with prior reports of 11\u0026ndash;15% in SLT/LDLT series \u003csup\u003e(\u003cspan additionalcitationids=\"CR24\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e)\u003c/sup\u003e, with graft configuration emerging as a critical determinant. Right-sided grafts demonstrated superior outcomes (3-year OS: 77.2% vs 57.8% for left grafts), suggesting surgical approach optimization may mitigate risks.\u003c/p\u003e \u003cp\u003eThe basic definition of EAD is that in the early stage after liver transplantation, the graft function is in a marginal state \u003csup\u003e(\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e)\u003c/sup\u003e. Our analysis also revealed significantly elevated risks of EAD and pleural effusion in adult HCC patients receiving SLT compared to WLT recipients (\u0026zwnj;EAD: 25.7% vs 16.8%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001; pleural effusion: 17.3% vs 9.9%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001\u0026zwnj;). Some EAD can progress to cause graft dysfunction, leading to death or re-transplantation, which is one of the most serious complications after liver transplantation.Similarly, a study from the United Kingdom also reported that the incidence of early liver failure was higher in SLT recipients using DBD-derived donors and extended right half liver grafts compared to recipients of WLT from DCD donors \u003csup\u003e(2\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e)\u003c/sup\u003e. Mechanistically, EAD may be precipitated by:Insufficient graft mass (SLT 1.4%vsWLT 2.1,P\u0026thinsp;\u0026lt;\u0026thinsp;0.001),preoperative hemoglobin of patients(SLT 69.2g/LvsWLT 104.9g/L mean,P\u0026thinsp;\u0026lt;\u0026thinsp;0.001),ABO-incompatible.\u003c/p\u003e \u003cp\u003eThrough comprehensive univariable and multivariable analyses, we identified several independent risk factors for OS in both HCC and non-HCC recipients. For HCC patients, these included donor body mass index (BMI), recipient BMI, Model for End-Stage Liver Disease (MELD) score\u0026thinsp;\u0026gt;\u0026thinsp;25, cold ischemia time (CIT), and exceeding Milan/Hangzhou criteria. In non-HCC recipients, age, CIT, and the type of transplantation (SLT vs. WLT) were independent predictors of mortality.The increase of donor BMI may be accompanied by liver steatosis, which increases the risk of primary graft nonfunction, especially in SLT, the functional reserve after fatty liver segmentation is further reduced. High BMI recipients are more likely to induce insulin resistance and dyslipidemia due to immunosuppressants, accelerate atherosclerosis, and lead to cardiovascular disease related death. CIT was identified as an independent risk factor for OS in both HCC and non HCC patients, which was consistent with many studies. Prolonged CIT can lead to ischemia-reperfusion injury. At the same time, in SLT, the segmentation process may further prolong CIT, especially in vitro splitting operation. High MELD scores are often associated with coagulation disorders and systemic inflammation, which increase the risk of intraoperative bleeding and postoperative sepsis. Age as a risk factor in non HCC patients may reflect the impact of coexisting diseases (such as cardiovascular disease and renal insufficiency) on surgical tolerance. Elderly patients are more prone to infection after operation. SLT is an independent risk factor in non-HCC ESLD patients, but not in HCC patients. This fact proved SLT is a safe and reliable option for adult HCC recipient.Despite SLT being identified as an independent risk factor for long-term survival in non-HCC patients (HR\u0026thinsp;=\u0026thinsp;1.555, 95% CI 1.209-2.000,p\u0026thinsp;\u0026lt;\u0026thinsp;0.05), our study revealed superior survival outcomes in recipients of right hemiliver and right trisegment grafts compared to left hemiliver grafts(3-year OS: 77.2% vs 57.8%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001)\u003c/p\u003e \u003cp\u003eWhile our study provides valuable insights into the outcomes of SLT in adult liver transplantation, it is not without limitations. As a retrospective study, it is susceptible to reporting biases and reflects the specific perioperative management strategies adopted by the participating transplant centers. Furthermore, the presented data may not be generalizable to transplant centers in other countries with different allocation rules and recipient selection policies.\u003c/p\u003e \u003cp\u003eIn conclusion, our findings support the adoption of SLT as a safe and reliable option for adult HCC patients, offering equivalent long-term survival outcomes to WLT. For non-HCC ESLD patients, optimization of graft type, with a preference for right-sided grafts, combined with minimization of CIT and stringent recipient selection, may maximize the benefits of SLT. Future studies with larger sample sizes and multicenter collaborations are warranted to further validate our findings and guide clinical practice in this area.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eHCC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ehepatocellular carcinoma\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNon-HCC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003enon hepatocellular carcinoma\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eESLD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eend stage liver disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eLT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eliver transplantation\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSLT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003esplit liver transplantation\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eWLT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ewhole liver transplantation\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ePSM\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003epropensity score matching\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMELD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003emodel for end-stage liver disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eAFP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ealpha fetoprotein\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGVHD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003egraft versus host disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eEAD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eearly allograft dysfunction\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eOS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eoverall survival\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDFS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003edisease-free survival\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eACKNOWLEDGMENTS:\u003c/strong\u003e This work was supported by grants from National Key Research and Development Program of China (2021YFA1100500), National Natural Science Foundation of China (92159202) and Key Research \u0026amp; Development Plan of Zhejiang Province (2022C03108).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONFLICT OF INTEREST STATEMENT:\u003c/strong\u003e The authors declare no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eETHICS STATEMENT:\u0026nbsp;\u003c/strong\u003eThe authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This was performed according to the Declaration of Helsinki and approved by the CLTR (No.\u0026nbsp;20230030).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eInformed consent: Informed consent was obtained from all the patients for the use of their data for research purposes. No organs from executed prisoners were used.\u003c/p\u003e\n\u003cp\u003eRegistry and the Registration No. of the study/trial: N/A.\u003c/p\u003e\n\u003cp\u003eAnimal studies: N/A.\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eWe, the undersigned authors, certify that each author has contributed significantly to the work and takes public responsibility for appropriate portions of the content. Specifically, the contributions are as follows:\u0026zwnj;Yunguo Lei\u0026zwnj; and \u0026zwnj;Jun Pan\u0026zwnj; (co-first authors): Designed the study, analyzed the data, and drafted the manuscript.\u0026zwnj;Zhe Yang\u0026zwnj; (co-first author): Participated in data analysis and manuscript preparation.\u0026zwnj;Jun Chen\u0026zwnj;: Provided critical revisions and intellectual input to the manuscript.\u0026zwnj;Beng Yang\u0026zwnj;: Assisted in data interpretation and manuscript editing.\u0026zwnj;Zhisheng Zhou\u0026zwnj;: Contributed to the data collection and analysis.\u0026zwnj;Shengjun Xu\u0026zwnj;: Provided intellectual input and critical revisions.\u0026zwnj;Kai Wang\u0026zwnj;: Assisted in data interpretation and manuscript preparation.\u0026zwnj;Ronggao Chen\u0026zwnj;: Participated in the study design and data collection.\u0026zwnj;Jinzhen Cai\u0026zwnj;: Contributed to data analysis and interpretation.\u0026zwnj;Shusen Zheng\u0026zwnj;: Provided intellectual input and critical revisions.\u0026zwnj;Qiang Wei\u0026zwnj; and \u0026zwnj;Xiao Xu\u0026zwnj; (co-corresponding authors): Supervised the study, contributed to the study design, data interpretation, and critical revisions of the manuscript.All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGoldaracena N, Echeverri J, Kehar M, DeAngelis M, Jones N, Ling S, et al. Pediatric living donor liver transplantation with large-for-size left lateral segment grafts. Am J Transplant. 2020;20(2):504\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSamuel D, De Martin E, Berg T, Berenguer M, Burra P, Fondevila C, et al. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81(6):1040\u0026ndash;86.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBusuttil RW, Goss JA. Split liver transplantation. Ann Surg. 1999;229(3):313\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAzoulay D, Castaing D, Adam R, Savier E, Delvart V, Karam V, et al. Split-liver transplantation for two adult recipients: feasibility and long-term outcomes. Ann Surg. 2001;233(4):565\u0026ndash;74.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHackl C, Schmidt KM, Susal C, Dohler B, Zidek M, Schlitt HJ. Split liver transplantation: Current developments. World J Gastroenterol. 2018;24(47):5312\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am J Transplant. 2023;23(2 Suppl 1):S178-S263.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAngelico R, Nardi A, Adam R, Nadalin S, Polak WG, Karam V, et al. Outcomes of left split graft transplantation in Europe: report from the European Liver Transplant Registry. Transpl Int. 2018;31(7):739\u0026ndash;50.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSasaki K, Firl DJ, McVey JC, Schold JD, Iuppa G, Diago Uso T, et al. Elevated Risk of Split-Liver grafts in adult liver Transplantation: Statistical Artifact or Nature of the Beast? Liver Transpl. 2019;25(5):741\u0026ndash;51.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHashimoto K, Fujiki M, Quintini C, Aucejo FN, Uso TD, Kelly DM, et al. Split liver transplantation in adults. World J Gastroenterol. 2016;22(33):7500\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGavriilidis P, Roberts KJ, Azoulay D. Right lobe split liver graft versus whole liver transplantation: A systematic review by updated traditional and cumulative meta-analysis. Dig Liver Dis. 2018;50(12):1274\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoss MW, Cescon M, Angelico R, Andorno E, Rossi G, Pinna A, et al. A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts. Liver Transpl. 2017;23(11):1384\u0026ndash;95.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFeng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6(4):783\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoussaoui D, Toso C, Nowacka A, McLin VA, Bednarkiewicz M, Andres A, et al. Early complications after liver transplantation in children and adults: Are split grafts equal to each other and equal to whole livers? Pediatr Transplant. 2017;21(4).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWan P, Li Q, Zhang J, Xia Q. Right lobe split liver transplantation versus whole liver transplantation in adult recipients: A systematic review and meta-analysis. Liver Transpl. 2015;21(7):928\u0026ndash;43.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang L, Zeng L, Gao X, Wang H, Zhu Y. Transformation of organ donation in China. Transpl Int. 2015;28(4):410\u0026ndash;5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBenedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg. 2018;53(6):1112\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12):1726\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMathew G, Agha R, Albrecht J, Goel P, Mukherjee I, Pai P, et al. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2021;96:106165.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOgawa K, Takada Y. Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2016;1:35.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu Z, Qian Z, Wu J, Zhou J, Zhang M, Zhou L, et al. Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation. Clin Res Hepatol Gastroenterol. 2016;40(3):315\u0026ndash;26.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMatsuoka LK, Sutcliffe T, Feurer ID, Rega SA, Ziogas IA, Izzy M, et al. Comparison of Survival Outcomes After Deceased Donor Split Versus Whole Liver Transplant for Hepatocellular Carcinoma. Exp Clin Transplant. 2021;19(8):811\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYao J, Lei YG, Yi HM, Yang Y. Clinical strategies to improve the survival rate of liver recipients with acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2023;22(1):41\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhong J, Smith C, Walker P, Sheridan M, Guthrie A, Albazaz R. Imaging post liver transplantation part I: vascular complications. Clin Radiol. 2020;75(11):845\u0026ndash;53.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDuffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, et al. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg. 2009;208(5):896\u0026ndash;903; discussion \u0026ndash;\u0026thinsp;5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKhalaf H. Vascular complications after deceased and living donor liver transplantation: a single-center experience. Transplant Proc. 2010;42(3):865\u0026thinsp;\u0026ndash;\u0026thinsp;70.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAgopian VG, Harlander-Locke MP, Markovic D, Dumronggittigule W, Xia V, Kaldas FM, et al. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model. JAMA Surg. 2018;153(5):436\u0026ndash;44.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMallik M, Callaghan CJ, Hope M, Gibbs P, Davies S, Gimson AE, et al. Comparison of liver transplantation outcomes from adult split liver and circulatory death donors. Br J Surg. 2012;99(6):839\u0026ndash;47.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-6432057/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6432057/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThis multicenter study (2018\u0026ndash;2022) compared split liver (SLT) vs. whole liver (WLT) transplantation in 5,978 adults (1,532 SLT; 4,446 WLT). Propensity-matched analysis showed HCC-SLT recipients had higher early allograft dysfunction (25.7% vs. 16.8%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) and pleural effusion (17.3% vs. 9.9%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) than HCC-WLT, while non-HCC ESLD-SLT recipients faced more intra-abdominal bleeding (13.5% vs. 8.5%, P\u0026thinsp;=\u0026thinsp;0.02) and vascular complications (4.7% vs. 1.9%, P\u0026thinsp;=\u0026thinsp;0.01). Despite these early risks, HCC cohorts achieved equivalent 5-year overall (OS) and disease-free survival (P\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Non-HCC ESLD recipients with right hemiliver/trisection grafts had superior 1-/3-year OS (82.2%/77.2% vs. 63.4%/57.8%, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) versus left hemiliver. Multivariate analysis identified donor BMI, MELD\u0026thinsp;\u0026gt;\u0026thinsp;25, prolonged cold ischemia time (CIT), and exceeding Milan/Hangzhou criteria as HCC survival risks; age, CIT, and graft type predicted non-HCC mortality. SLT offers oncologically safe, long-term outcomes for HCC comparable to WLT with strict selection, while right-graft optimization and CIT reduction improve non-HCC ESLD survival.\u003c/p\u003e","manuscriptTitle":"Comparative Outcomes of Split versus Whole Liver Transplantation in Adult ESLD Recipients: A Multicenter Propensity-Matched Analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-05-05 20:21:39","doi":"10.21203/rs.3.rs-6432057/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"21f79e26-b96b-4ea0-aa2f-1acd54f989d4","owner":[],"postedDate":"May 5th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":47850575,"name":"Health sciences/Gastroenterology/Hepatology/Liver"},{"id":47850576,"name":"Health sciences/Gastroenterology/Hepatology/Liver diseases"}],"tags":[],"updatedAt":"2025-07-16T17:38:29+00:00","versionOfRecord":[],"versionCreatedAt":"2025-05-05 20:21:39","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6432057","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6432057","identity":"rs-6432057","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}